European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022
A unique collaboration of multidisciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on cutaneous melanoma diagnosis and treatme...
Gespeichert in:
| Veröffentlicht in: | European journal of cancer (1990) Jg. 170; S. 256 - 284 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
England
Elsevier Ltd
01.07.2022
Elsevier Science Ltd Elsevier |
| Schlagworte: | |
| ISSN: | 0959-8049, 1879-0852, 1879-0852 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | A unique collaboration of multidisciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on cutaneous melanoma diagnosis and treatment, based on the systematic literature reviews and the experts' experience. Cutaneous melanomas are excised with one to 2-cm safety margins. Sentinel lymph node dissection shall be performed as a staging procedure in patients with tumor thickness ≥1.0 mm or ≥0.8 mm with additional histological risk factors, although there is as yet no clear survival benefit for this approach. Therapeutic decisions in stage III/IV patients should be primarily made by an interdisciplinary oncology team (“tumor board”). Adjuvant therapies can be proposed in stage III/completely resected stage IV patients and are primarily anti-PD-1, independent of mutational status, or alternatively dabrafenib plus trametinib for BRAF mutant patients. In distant metastases (stage IV), either resected or not, systemic treatment is always indicated. For first-line treatment particularly in BRAF wild-type patients, immunotherapy with PD-1 antibodies alone or in combination with CTLA-4 antibodies shall be considered. In stage IV melanoma with a BRAF-V600 E/K mutation, first-line therapy with BRAF/MEK inhibitors can be offered as an alternative to immunotherapy. In patients with primary resistance to immunotherapy and harboring a BRAF-V600 E/K mutation, this therapy shall be offered as second-line therapy. Systemic therapy in stage III/IV melanoma is a rapidly changing landscape, and it is likely that these recommendations may change in the near future. |
|---|---|
| AbstractList | A unique collaboration of multidisciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on cutaneous melanoma diagnosis and treatment, based on the systematic literature reviews and the experts' experience. Cutaneous melanomas are excised with one to 2-cm safety margins. Sentinel lymph node dissection shall be performed as a staging procedure in patients with tumor thickness ≥1.0 mm or ≥0.8 mm with additional histological risk factors, although there is as yet no clear survival benefit for this approach. Therapeutic decisions in stage III/IV patients should be primarily made by an interdisciplinary oncology team ("tumor board"). Adjuvant therapies can be proposed in stage III/completely resected stage IV patients and are primarily anti-PD-1, independent of mutational status, or alternatively dabrafenib plus trametinib for BRAF mutant patients. In distant metastases (stage IV), either resected or not, systemic treatment is always indicated. For first-line treatment particularly in BRAF wild-type patients, immunotherapy with PD-1 antibodies alone or in combination with CTLA-4 antibodies shall be considered. In stage IV melanoma with a BRAF-V600 E/K mutation, first-line therapy with BRAF/MEK inhibitors can be offered as an alternative to immunotherapy. In patients with primary resistance to immunotherapy and harboring a BRAF-V600 E/K mutation, this therapy shall be offered as second-line therapy. Systemic therapy in stage III/IV melanoma is a rapidly changing landscape, and it is likely that these recommendations may change in the near future. A unique collaboration of multidisciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on cutaneous melanoma diagnosis and treatment, based on the systematic literature reviews and the experts' experience. Cutaneous melanomas are excised with one to 2-cm safety margins. Sentinel lymph node dissection shall be performed as a staging procedure in patients with tumor thickness ≥1.0 mm or ≥0.8 mm with additional histological risk factors, although there is as yet no clear survival benefit for this approach. Therapeutic decisions in stage III/IV patients should be primarily made by an interdisciplinary oncology team ("tumor board"). Adjuvant therapies can be proposed in stage III/completely resected stage IV patients and are primarily anti-PD-1, independent of mutational status, or alternatively dabrafenib plus trametinib for BRAF mutant patients. In distant metastases (stage IV), either resected or not, systemic treatment is always indicated. For first-line treatment particularly in BRAF wild-type patients, immunotherapy with PD-1 antibodies alone or in combination with CTLA-4 antibodies shall be considered. In stage IV melanoma with a BRAF-V600 E/K mutation, first-line therapy with BRAF/MEK inhibitors can be offered as an alternative to immunotherapy. In patients with primary resistance to immunotherapy and harboring a BRAF-V600 E/K mutation, this therapy shall be offered as second-line therapy. Systemic therapy in stage III/IV melanoma is a rapidly changing landscape, and it is likely that these recommendations may change in the near future. A unique collaboration of multidisciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on cutaneous melanoma diagnosis and treatment, based on the systematic literature reviews and the experts' experience. Cutaneous melanomas are excised with one to 2-cm safety margins. Sentinel lymph node dissection shall be performed as a staging procedure in patients with tumor thickness ≥1.0 mm or ≥0.8 mm with additional histological risk factors, although there is as yet no clear survival benefit for this approach. Therapeutic decisions in stage III/IV patients should be primarily made by an interdisciplinary oncology team ("tumor board"). Adjuvant therapies can be proposed in stage III/completely resected stage IV patients and are primarily anti-PD-1, independent of mutational status, or alternatively dabrafenib plus trametinib for BRAF mutant patients. In distant metastases (stage IV), either resected or not, systemic treatment is always indicated. For first-line treatment particularly in BRAF wild-type patients, immunotherapy with PD-1 antibodies alone or in combination with CTLA-4 antibodies shall be considered. In stage IV melanoma with a BRAF-V600 E/K mutation, first-line therapy with BRAF/MEK inhibitors can be offered as an alternative to immunotherapy. In patients with primary resistance to immunotherapy and harboring a BRAF-V600 E/K mutation, this therapy shall be offered as second-line therapy. Systemic therapy in stage III/IV melanoma is a rapidly changing landscape, and it is likely that these recommendations may change in the near future.A unique collaboration of multidisciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on cutaneous melanoma diagnosis and treatment, based on the systematic literature reviews and the experts' experience. Cutaneous melanomas are excised with one to 2-cm safety margins. Sentinel lymph node dissection shall be performed as a staging procedure in patients with tumor thickness ≥1.0 mm or ≥0.8 mm with additional histological risk factors, although there is as yet no clear survival benefit for this approach. Therapeutic decisions in stage III/IV patients should be primarily made by an interdisciplinary oncology team ("tumor board"). Adjuvant therapies can be proposed in stage III/completely resected stage IV patients and are primarily anti-PD-1, independent of mutational status, or alternatively dabrafenib plus trametinib for BRAF mutant patients. In distant metastases (stage IV), either resected or not, systemic treatment is always indicated. For first-line treatment particularly in BRAF wild-type patients, immunotherapy with PD-1 antibodies alone or in combination with CTLA-4 antibodies shall be considered. In stage IV melanoma with a BRAF-V600 E/K mutation, first-line therapy with BRAF/MEK inhibitors can be offered as an alternative to immunotherapy. In patients with primary resistance to immunotherapy and harboring a BRAF-V600 E/K mutation, this therapy shall be offered as second-line therapy. Systemic therapy in stage III/IV melanoma is a rapidly changing landscape, and it is likely that these recommendations may change in the near future. |
| Author | Hoeller, Christoph Arenberger, Petr Bastholt, Lars Zalaudek, Iris Nathan, Paul Dréno, Brigitte Malvehy, Josep Saiag, Philippe Kelleners-Smeets, Nicole Vieira, Ricardo Basset-Seguin, Nicole Van Akkooi, Alexander C.J. Lallas, Aimilios Forsea, Ana-Maria Hauschild, Axel Moreno-Ramirez, David Pellacani, Giovanni Bataille, Veronique Stratigos, Alexander J. Amaral, Teresa Peris, Ketty Fargnoli, Maria C. Lebbé, Celeste Grob, Jean-Jacques Lytvynenko, Bodhan Garbe, Claus Kaufmann, Roland del Marmol, Veronique Lorigan, Paul |
| Author_xml | – sequence: 1 givenname: Claus surname: Garbe fullname: Garbe, Claus email: claus.garbe@med.uni-tuebingen.de organization: Center for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany – sequence: 2 givenname: Teresa surname: Amaral fullname: Amaral, Teresa organization: Center for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany – sequence: 3 givenname: Ketty surname: Peris fullname: Peris, Ketty organization: Institute of Dermatology, Università Cattolica, Rome, Italy – sequence: 4 givenname: Axel surname: Hauschild fullname: Hauschild, Axel organization: Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany – sequence: 5 givenname: Petr surname: Arenberger fullname: Arenberger, Petr organization: Department of Dermatovenereology, Third Faculty of Medicine, Charles University, Prague, Czech Republic – sequence: 6 givenname: Nicole surname: Basset-Seguin fullname: Basset-Seguin, Nicole organization: Université Paris Cite, AP-HP, Department of Dermatology INSERM U 976 Hôpital, Saint Louis Paris France – sequence: 7 givenname: Lars surname: Bastholt fullname: Bastholt, Lars organization: Department of Oncology, Odense University Hospital, Odense, Denmark – sequence: 8 givenname: Veronique surname: Bataille fullname: Bataille, Veronique organization: Twin Research and Genetic Epidemiology Unit, School of Basic & Medical Biosciences, King's College London, London, SE1 7EH, United Kingdom – sequence: 9 givenname: Veronique surname: del Marmol fullname: del Marmol, Veronique organization: Department of Dermatology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium – sequence: 10 givenname: Brigitte surname: Dréno fullname: Dréno, Brigitte organization: Dermatology Department, CHU Nantes, CIC 1413, CRCINA, University Nantes, Nantes, France – sequence: 11 givenname: Maria C. surname: Fargnoli fullname: Fargnoli, Maria C. organization: Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy – sequence: 12 givenname: Ana-Maria surname: Forsea fullname: Forsea, Ana-Maria organization: Dermatology Department, Elias University Hospital, Carol Davila University of Medicine and Pharmacy Bucharest, Romania – sequence: 13 givenname: Jean-Jacques surname: Grob fullname: Grob, Jean-Jacques organization: University Department of Dermatology, Marseille, France – sequence: 14 givenname: Christoph surname: Hoeller fullname: Hoeller, Christoph organization: Department of Dermatology, Medical University of Vienna, Austria – sequence: 15 givenname: Roland surname: Kaufmann fullname: Kaufmann, Roland organization: Department of Dermatology, Venereology and Allergology, Frankfurt University Hospital, Frankfurt, Germany – sequence: 16 givenname: Nicole surname: Kelleners-Smeets fullname: Kelleners-Smeets, Nicole organization: Department of Dermatology, Maastricht University Medical Center+, Maastricht, Netherlands – sequence: 17 givenname: Aimilios surname: Lallas fullname: Lallas, Aimilios organization: First Department of Dermatology, Aristotle University, Thessaloniki, Greece – sequence: 18 givenname: Celeste surname: Lebbé fullname: Lebbé, Celeste organization: Université Paris Cite, AP-HP, Department of Dermatology INSERM U 976 Hôpital, Saint Louis Paris France – sequence: 19 givenname: Bodhan surname: Lytvynenko fullname: Lytvynenko, Bodhan organization: Shupyk National Medical Academy of Postgraduate Education, Kiev, Ukraine – sequence: 20 givenname: Josep surname: Malvehy fullname: Malvehy, Josep organization: Melanoma Unit, Department of Dermatology, Hospital Clinic, IDIBAPS, Barcelona, Spain – sequence: 21 givenname: David surname: Moreno-Ramirez fullname: Moreno-Ramirez, David organization: Medical-&-Surgical Dermatology Service, Hospital Universitario Virgen Macarena, Sevilla, Spain – sequence: 22 givenname: Paul surname: Nathan fullname: Nathan, Paul organization: Mount-Vernon Cancer Centre, Northwood United Kingdom – sequence: 23 givenname: Giovanni surname: Pellacani fullname: Pellacani, Giovanni organization: Dermatology Unit, University of Modena and Reggio Emilia, Modena, Italy – sequence: 24 givenname: Philippe surname: Saiag fullname: Saiag, Philippe organization: University Department of Dermatology, Université de Versailles-Saint Quentin en Yvelines, APHP, Boulogne, France – sequence: 25 givenname: Alexander J. surname: Stratigos fullname: Stratigos, Alexander J. organization: First Department of Dermatology, University of Athens School of Medicine, Andreas Sygros Hospital, Athens, Greece – sequence: 26 givenname: Alexander C.J. surname: Van Akkooi fullname: Van Akkooi, Alexander C.J. organization: Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia – sequence: 27 givenname: Ricardo surname: Vieira fullname: Vieira, Ricardo organization: Department of Dermatology and Venereology, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal – sequence: 28 givenname: Iris surname: Zalaudek fullname: Zalaudek, Iris organization: Dermatology Clinic, Maggiore Hospital, University of Trieste, Trieste, Italy – sequence: 29 givenname: Paul surname: Lorigan fullname: Lorigan, Paul organization: The University of Manchester, Oxford Rd, Manchester, M13 9PL, United Kingdom |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35623961$$D View this record in MEDLINE/PubMed https://hal.science/hal-03775755$$DView record in HAL |
| BookMark | eNqFkcFu1DAQhi1URLeFF-CALHGBQ4LtOLFTcamqQpFWgkN7thxnAg6JHWynUt8eR1t62EM52Rp9nz0z_xk6cd4BQm8pKSmhzaexhNHokhHGSsJLQuULtKNStAWRNTtBO9LWbSEJb0_RWYwjIURITl6h06puWNU2dIe66zX4BbTDxrsILq6x6HSEHluXIPQ2GrtM1unwgH-utod8Bzz4gGeYtPOzLvEPHRJmF_g2gE4zuIQLfLf0OgHeenuNXg56ivDm8TxHd1-ub69uiv33r9-uLveFqUWbCg6igaYmYHpeyb5ppa4INUQPgjeM8043dU9rOYDpaC5SCaIVhlMNnAog1Tn6eHj3l57UEuyce1ZeW3VzuVdbjVRC1KKu72lmPxzYJfg_K8Sk5jwpTHkk8GtUrBGUiYZQltH3R-jo1-DyJJlqqWSS0e3zd4_U2s3QP_3_b9MZYAfABB9jgOEJoURtcapRbXGqbWWKcJXjzJI8koxNOlnvUtB2el79fFAhr_zeQlA5SXAGehvAJNV7-7x-caSbnLw1evoND_-T_wKzestD |
| CitedBy_id | crossref_primary_10_1016_j_ijbiomac_2025_145320 crossref_primary_10_3389_fonc_2024_1366532 crossref_primary_10_3390_cancers14225672 crossref_primary_10_1016_j_ctrv_2025_102889 crossref_primary_10_1016_j_ejca_2025_115403 crossref_primary_10_3390_jcm13175238 crossref_primary_10_3390_jimaging11040107 crossref_primary_10_1007_s11523_025_01164_2 crossref_primary_10_1038_s41415_024_7084_6 crossref_primary_10_1111_pcmr_70034 crossref_primary_10_1186_s42047_025_00178_4 crossref_primary_10_1097_DSS_0000000000004612 crossref_primary_10_3390_ph16050746 crossref_primary_10_1016_S0140_6736_23_00821_8 crossref_primary_10_1016_j_ejca_2023_04_018 crossref_primary_10_1038_s41420_023_01496_w crossref_primary_10_3390_jcm13092527 crossref_primary_10_1016_j_ejso_2023_107053 crossref_primary_10_1016_j_ejso_2025_110225 crossref_primary_10_1097_CMR_0000000000000999 crossref_primary_10_1002_lio2_70232 crossref_primary_10_1001_jamanetworkopen_2023_56479 crossref_primary_10_3389_fmed_2024_1436078 crossref_primary_10_1016_j_ejphar_2025_177992 crossref_primary_10_1097_CMR_0000000000000915 crossref_primary_10_3390_cancers15184468 crossref_primary_10_1093_ced_llad107 crossref_primary_10_1016_j_canlet_2024_216911 crossref_primary_10_1097_CMR_0000000000000994 crossref_primary_10_2340_actadv_v104_40064 crossref_primary_10_1093_bjd_ljad125 crossref_primary_10_3390_ijms23126752 crossref_primary_10_1007_s11912_023_01385_6 crossref_primary_10_1007_s00432_023_05415_5 crossref_primary_10_1016_j_jconrel_2024_01_057 crossref_primary_10_1038_s41435_024_00278_3 crossref_primary_10_1111_ddg_15699_g crossref_primary_10_1007_s12094_024_03608_z crossref_primary_10_1016_j_cellsig_2024_111439 crossref_primary_10_36290_xon_2025_028 crossref_primary_10_3390_medicina60060884 crossref_primary_10_1002_cyto_b_22236 crossref_primary_10_1016_j_omtn_2024_102283 crossref_primary_10_3390_diagnostics15111357 crossref_primary_10_1007_s10238_023_01107_z crossref_primary_10_1016_j_eurpolymj_2024_113282 crossref_primary_10_1111_1346_8138_17068 crossref_primary_10_2340_actadv_v104_40535 crossref_primary_10_3389_fonc_2023_1237643 crossref_primary_10_3390_cancers15194799 crossref_primary_10_1186_s12943_024_01950_y crossref_primary_10_1016_j_ejso_2023_107249 crossref_primary_10_1158_1078_0432_CCR_25_0884 crossref_primary_10_1016_j_prp_2025_156188 crossref_primary_10_1093_bjd_ljae377 crossref_primary_10_1002_ima_22912 crossref_primary_10_1007_s12672_025_02888_3 crossref_primary_10_4081_dr_2024_9919 crossref_primary_10_7759_cureus_45425 crossref_primary_10_1007_s00403_024_02834_3 crossref_primary_10_1111_ans_70252 crossref_primary_10_3390_diagnostics14131323 crossref_primary_10_3390_diagnostics13172790 crossref_primary_10_1007_s12325_023_02555_5 crossref_primary_10_3390_ijms241310919 crossref_primary_10_3390_ijms241814403 crossref_primary_10_1111_ddg_15645_g crossref_primary_10_3390_cancers16122193 crossref_primary_10_1016_j_suc_2025_03_003 crossref_primary_10_2174_0109298673282799231211113347 crossref_primary_10_3390_diagnostics13091617 crossref_primary_10_1016_j_ad_2023_05_023 crossref_primary_10_1016_j_abdp_2025_501139 crossref_primary_10_1111_jdv_20679 crossref_primary_10_3390_medicina60030351 crossref_primary_10_1097_CMR_0000000000000934 crossref_primary_10_3390_cancers15153818 crossref_primary_10_1038_s41591_024_03411_x crossref_primary_10_29254_2077_4214_2022_4_167_92_98 crossref_primary_10_1002_jum_16180 crossref_primary_10_3390_cancers15072174 crossref_primary_10_3390_molecules29225239 crossref_primary_10_1002_cam4_6012 crossref_primary_10_1667_RADE_22_0086_1 crossref_primary_10_1016_j_soc_2024_12_007 crossref_primary_10_1080_20450885_2024_2382079 crossref_primary_10_1007_s13555_025_01363_9 crossref_primary_10_1111_ddg_15809 crossref_primary_10_1080_14737140_2024_2336106 crossref_primary_10_1186_s12935_024_03220_9 crossref_primary_10_3390_cancers15215265 crossref_primary_10_1111_ddg_15645 crossref_primary_10_3390_clinpract14010018 crossref_primary_10_3389_fimmu_2024_1469096 crossref_primary_10_3390_ijms23147653 crossref_primary_10_1111_jdv_18880 crossref_primary_10_1186_s12935_024_03625_6 crossref_primary_10_1007_s00432_023_05064_8 crossref_primary_10_1136_jitc_2023_006821 crossref_primary_10_3390_app142110054 crossref_primary_10_2478_amb_2025_0050 crossref_primary_10_1177_17531934241245028 crossref_primary_10_26508_lsa_202402671 crossref_primary_10_3390_cancers16213679 crossref_primary_10_3390_molecules28124776 crossref_primary_10_4081_dr_2025_10349 crossref_primary_10_1038_s41598_025_08669_w crossref_primary_10_1001_jamadermatol_2025_0318 crossref_primary_10_1007_s10151_024_03086_z crossref_primary_10_1080_20450885_2024_2432826 crossref_primary_10_1186_s12885_023_10560_8 crossref_primary_10_3390_ijms25063453 crossref_primary_10_1038_s41467_023_43980_y crossref_primary_10_1111_ddg_15699 crossref_primary_10_1186_s12935_023_03048_9 crossref_primary_10_1109_JBHI_2024_3465929 crossref_primary_10_3390_cancers15041074 crossref_primary_10_3389_fimmu_2024_1486680 crossref_primary_10_3390_ijms242115847 crossref_primary_10_1111_jdv_20138 crossref_primary_10_1016_j_intimp_2024_111989 crossref_primary_10_1097_CMR_0000000000000959 crossref_primary_10_1016_j_banm_2023_03_019 crossref_primary_10_1002_cam4_6438 crossref_primary_10_3389_fmed_2023_1293397 crossref_primary_10_1007_s12254_023_00881_6 crossref_primary_10_1016_j_intimp_2023_111000 crossref_primary_10_1016_j_ejca_2024_115053 crossref_primary_10_57187_s_4210 crossref_primary_10_1016_j_ad_2023_10_036 crossref_primary_10_3390_cancers17081281 crossref_primary_10_1136_bjo_2024_326691 crossref_primary_10_1111_jdv_20816 crossref_primary_10_3390_ijms23169327 crossref_primary_10_1007_s12094_024_03579_1 crossref_primary_10_1016_j_pharmthera_2022_108301 crossref_primary_10_1101_gad_350078_122 crossref_primary_10_1016_j_abd_2025_501139 crossref_primary_10_1111_jdv_20524 crossref_primary_10_3389_fimmu_2025_1608215 crossref_primary_10_1002_bcp_70172 crossref_primary_10_2340_actadv_v104_41029 crossref_primary_10_1093_ced_llae129 crossref_primary_10_1016_j_ejca_2025_115788 crossref_primary_10_3390_ijms25052984 crossref_primary_10_1007_s11864_024_01289_y crossref_primary_10_1016_j_ejso_2024_107969 crossref_primary_10_3390_cancers16172981 crossref_primary_10_1007_s12325_024_02883_0 crossref_primary_10_1080_20450885_2025_2545167 crossref_primary_10_3390_diagnostics14070688 crossref_primary_10_1080_20479700_2023_2284464 crossref_primary_10_3390_cancers16122272 crossref_primary_10_1007_s00403_024_03376_4 crossref_primary_10_3390_ijms24054961 crossref_primary_10_1007_s11523_024_01041_4 crossref_primary_10_1002_jvc2_544 crossref_primary_10_1016_j_ajpath_2023_08_013 crossref_primary_10_3390_cancers16111951 crossref_primary_10_1111_jdv_19920 crossref_primary_10_2217_epi_2023_0139 crossref_primary_10_1016_j_prp_2024_155262 crossref_primary_10_3390_cimb46090562 crossref_primary_10_1016_j_jcms_2024_08_007 crossref_primary_10_1245_s10434_024_16418_y crossref_primary_10_3390_ijms241914535 crossref_primary_10_1016_j_ejcskn_2024_100023 crossref_primary_10_1016_j_jcjo_2024_05_010 crossref_primary_10_1016_j_annonc_2024_08_2330 crossref_primary_10_1002_jvc2_254 crossref_primary_10_1007_s13555_023_00993_1 crossref_primary_10_1016_j_canrad_2024_03_006 crossref_primary_10_3390_cancers16122204 crossref_primary_10_1007_s11912_024_01556_z crossref_primary_10_1038_s41598_024_61150_y crossref_primary_10_3390_ijms25136942 crossref_primary_10_1001_jamadermatol_2025_3078 crossref_primary_10_1016_j_esmoop_2025_105053 crossref_primary_10_1186_s12967_023_04100_y crossref_primary_10_3390_cancers14194652 |
| Cites_doi | 10.1200/JCO.2020.38.15_suppl.10019 10.1111/jdv.14085 10.1200/JCO.18.02306 10.1016/j.ejca.2019.11.016 10.1200/JCO.2017.75.7724 10.1002/1097-0142(19880115)61:2<243::AID-CNCR2820610207>3.0.CO;2-K 10.1038/s41467-021-25332-w 10.1016/S0140-6736(11)61546-8 10.1245/s10434-020-08478-7 10.1016/S1470-2045(19)30151-2 10.1056/NEJMoa1503093 10.1056/NEJMoa1112302 10.1016/S0140-6736(12)60398-5 10.1002/cncr.22988 10.1093/annonc/mdu266 10.1016/j.ejca.2019.07.001 10.1038/bjc.2012.306 10.1200/JCO.18.01998 10.1056/NEJMoa1200690 10.1200/JCO.1995.13.4.910 10.1016/S0140-6736(01)06068-8 10.1016/S1470-2045(17)30180-8 10.1111/bjd.14325 10.1056/NEJMoa1103782 10.1200/jco.2007.25.18_suppl.8508 10.1093/annonc/mdy424.057 10.1002/jso.20305 10.1200/JCO.2019.37.15_suppl.TPS9600 10.1016/j.prro.2021.04.002 10.1245/s10434-021-10775-8 10.1016/S1470-2045(19)30388-2 10.1056/NEJMoa1709030 10.1016/S1470-2045(18)30700-9 10.1111/j.1365-2133.2010.09883.x 10.1186/s40425-017-0242-5 10.1158/1078-0432.CCR-21-0793 10.1016/S1470-2045(12)70090-6 10.1093/annonc/mdu344.46 10.1093/annonc/mdv623 10.1016/S0140-6736(05)67482-X 10.1001/jamaoncol.2018.4610 10.1056/NEJMoa1104621 10.1159/000497211 10.3390/cancers12041027 10.1046/j.1365-2133.2002.04750.x 10.1016/S1470-2045(18)30106-2 10.1097/SAP.0b013e31816714c8 10.1093/annonc/mdz011 10.1093/annonc/mdq438 10.1054/bjoc.2000.1623 10.1111/j.1365-2133.2005.07068.x 10.1016/j.radonc.2018.08.025 10.1016/j.ejca.2011.04.030 10.1186/s40425-019-0800-0 10.1093/annonc/mdx225 10.1038/s41591-020-01188-3 10.1200/JCO.2014.58.3377 10.1158/1538-7445.AM2021-CT008 10.1056/NEJMoa1709684 10.1016/j.ejca.2003.07.004 10.1056/NEJMoa1412690 10.1056/NEJMoa060992 10.1200/JCO.2021.39.15_suppl.9525 10.1200/JCO.2018.36.15_suppl.3062 10.1007/BF00684883 10.6004/jnccn.2009.0020 10.3389/fonc.2020.602705 10.1016/j.jtcvs.2006.08.065 10.1016/S1470-2045(18)30142-6 10.1245/s10434-021-09866-3 10.1016/S1470-2045(10)70288-6 10.1002/path.2804 10.1097/01.sla.0000181092.50141.fa 10.1200/JCO.2000.18.1.158 10.1016/S1470-2045(20)30494-0 10.1093/annonc/mdn001 10.3390/cells10092320 10.1016/j.ad.2011.12.009 10.1016/S0140-6736(08)61033-8 10.1016/j.ejca.2021.11.022 10.1200/JCO.2020.38.15_suppl.10000 10.1016/j.ejso.2021.02.025 10.1056/NEJMoa1412082 10.1016/j.ejso.2008.04.011 10.1200/JCO.2021.39.15_suppl.9502 10.1200/JCO.1998.16.4.1425 10.1016/S1470-2045(17)30429-1 10.1097/CMR.0000000000000764 10.1056/NEJMoa1613210 10.1016/S0140-6736(97)12445-X 10.4161/onci.28780 10.1200/JCO.2018.36.15_suppl.9504 10.1136/jitc-2019-000333 10.1016/S0140-6736(20)30417-7 10.1097/CMR.0b013e3282f702bf 10.1200/JCO.2014.56.2736 10.1371/journal.pone.0188602 10.1200/JCO.2009.23.4799 10.1200/jco.2014.32.15_suppl.9011 10.1097/DSS.0000000000003268 10.1200/JCO.2005.05.2498 10.1097/00008390-200104000-00015 10.1200/JCO.2020.38.15_suppl.10001 10.1158/1078-0432.CCR-21-0809 10.1016/S1470-2045(15)70122-1 10.1245/s10434-011-2030-7 10.1016/j.semradonc.2014.07.003 10.1016/S1470-2045(12)70138-9 10.1016/j.soc.2006.10.013 10.1016/j.jaad.2015.02.008 10.1056/NEJMoa1003466 10.1186/s40425-019-0623-z 10.1056/NEJMoa1805453 10.1126/science.aaa4967 10.1056/NEJMoa1802357 10.1200/JCO.2021.39.15_suppl.9500 10.1016/j.ejca.2020.04.030 10.1016/0360-3016(81)90007-9 10.1158/1535-7163.MCT-11-0989 10.1097/00008390-200302000-00016 10.1093/annonc/mdy408 10.1001/jamadermatol.2017.3114 10.1001/archsurg.1992.01420040034005 10.1016/S1470-2045(17)30414-X 10.1016/j.clindermatol.2009.06.013 10.1016/S1470-2045(18)30139-6 10.1002/cncr.21611 10.1097/00000658-199110000-00013 10.1016/S0140-6736(13)60802-8 10.1016/j.ctrv.2015.10.013 10.1200/JCO.2021.39.15_suppl.9506 10.1016/j.ejca.2018.12.023 10.1016/j.ejca.2015.07.013 10.1200/JCO.2004.03.185 10.1200/JCO.2006.06.0483 10.1056/NEJMoa1504030 10.1200/JCO.2021.39.15_suppl.9503 10.1016/j.amjsurg.2005.08.020 10.1200/JCO.2021.39.15_suppl.9504 10.1016/j.annonc.2021.08.1421 10.1001/archderm.144.7.943 10.1007/BF02985163 10.1200/JCO.2021.39.36_suppl.356154 10.1056/NEJMoa1310460 10.1245/s10434-016-5137-z 10.1016/S1470-2045(15)00482-9 10.1002/jso.21903 10.1056/NEJMoa1708539 10.1200/JCO.2021.39.15_suppl.9507 10.1016/S0151-9638(05)79450-3 10.1016/0360-3016(88)90118-6 10.1097/00008390-199910000-00009 10.1200/JCO.2021.39.15_suppl.9516 10.3390/cancers12092359 10.1056/NEJMoa1611299 10.47102/annals-acadmedsg.V39N8p634 10.1016/S1470-2045(17)30441-2 10.1002/1097-0142(19880915)62:6<1061::AID-CNCR2820620607>3.0.CO;2-X 10.1016/S1470-2045(21)00097-8 10.1200/JCO.2017.35.15_suppl.9507 10.1016/S1470-2045(15)00187-4 10.1200/JCO.2021.39.15_suppl.9508 10.1111/bjd.20407 10.1016/S1470-2045(16)30122-X 10.1056/NEJMoa1904059 10.1016/S0140-6736(18)31559-9 10.1016/S1470-2045(16)00141-8 10.1056/NEJMoa1910836 10.1097/CMR.0000000000000761 10.1200/JCO.1996.14.1.7 10.1016/j.ejca.2020.02.016 10.1016/j.ejca.2020.02.021 10.1200/JCO.2000.18.12.2444 10.1097/00008390-199912000-00012 10.1097/00042728-200802000-00002 10.1016/j.ejca.2020.07.017 10.1016/S1470-2045(14)70301-8 10.1200/JCO.1995.13.11.2776 10.1016/S1470-2045(12)70431-X 10.1056/NEJMoa2103485 10.1016/j.annonc.2020.04.471 10.1016/S1470-2045(15)00087-X 10.1056/NEJMoa1408868 10.1200/JCO.2010.33.9275 10.1097/00000478-199912000-00006 |
| ContentType | Journal Article |
| Copyright | 2022 The Authors 2022 Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. Copyright Elsevier Science Ltd. Jul 2022 Attribution - NonCommercial - NoDerivatives |
| Copyright_xml | – notice: 2022 The Authors – notice: 2022 – notice: Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. – notice: Copyright Elsevier Science Ltd. Jul 2022 – notice: Attribution - NonCommercial - NoDerivatives |
| CorporateAuthor | European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC) |
| CorporateAuthor_xml | – name: European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC) |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7TO 7U7 C1K H94 K9. NAPCQ 7X8 1XC VOOES |
| DOI | 10.1016/j.ejca.2022.04.018 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Oncogenes and Growth Factors Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Oncogenes and Growth Factors Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | MEDLINE AIDS and Cancer Research Abstracts MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1879-0852 |
| EndPage | 284 |
| ExternalDocumentID | oai:HAL:hal-03775755v1 35623961 10_1016_j_ejca_2022_04_018 S0959804922002283 |
| Genre | Journal Article Practice Guideline Review |
| GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29G 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 6PF 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABFNM ABGSF ABJNI ABLJU ABMAC ABMZM ABOCM ABUDA ABWVN ABXDB ACDAQ ACIEU ACIUM ACLOT ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADUVX AEBSH AEHWI AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRAH AFRHN AFTJW AFXIZ AGHFR AGQPQ AGRDE AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HED HMK HMO HVGLF HZ~ IHE J1W K-O KOM M29 M41 MO0 N9A O-L O9- OAUVE OC~ OO- OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSU SSZ T5K UV1 WUQ X7M XPP Z5R ZGI ZXP ~G- ~HD AACTN AFCTW RIG 9DU AAYXX CITATION AGCQF AGRNS CGR CUY CVF ECM EIF NPM 7TO 7U7 C1K H94 K9. NAPCQ 7X8 1XC VOOES |
| ID | FETCH-LOGICAL-c579t-4e76e650ecd438d698a301c0af746244ba65d158fecb1af718e797c41ae417e03 |
| ISICitedReferencesCount | 192 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000833527200004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0959-8049 1879-0852 |
| IngestDate | Sat Nov 29 14:57:43 EST 2025 Thu Oct 02 11:17:48 EDT 2025 Tue Oct 07 06:55:37 EDT 2025 Mon Jul 21 06:04:42 EDT 2025 Sat Nov 29 07:06:17 EST 2025 Tue Nov 18 21:23:30 EST 2025 Sun Apr 06 06:53:01 EDT 2025 Tue Oct 14 19:39:29 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Metastasectomy Interferon-α Cutaneous melanoma Tumor thickness Adjuvant treatment Systemic treatment Sentinel lymph node dissection Excisional margins |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. Attribution - NonCommercial - NoDerivatives: http://creativecommons.org/licenses/by-nc-nd |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c579t-4e76e650ecd438d698a301c0af746244ba65d158fecb1af718e797c41ae417e03 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Instructional Material/Guideline-3 ObjectType-Review-4 content type line 23 |
| ORCID | 0000-0002-8875-2164 0000-0002-5914-9171 0000-0001-5574-5825 0000-0002-7222-2951 0000-0002-4800-5877 0000-0002-7193-0964 0000-0002-1301-7974 0000-0002-7249-2556 0000-0002-3262-6935 0000-0001-5478-9826 0000-0001-8530-780X 0000-0002-7878-4955 |
| OpenAccessLink | https://hal.science/hal-03775755 |
| PMID | 35623961 |
| PQID | 2691828210 |
| PQPubID | 2047469 |
| PageCount | 29 |
| ParticipantIDs | hal_primary_oai_HAL_hal_03775755v1 proquest_miscellaneous_2671276012 proquest_journals_2691828210 pubmed_primary_35623961 crossref_primary_10_1016_j_ejca_2022_04_018 crossref_citationtrail_10_1016_j_ejca_2022_04_018 elsevier_sciencedirect_doi_10_1016_j_ejca_2022_04_018 elsevier_clinicalkey_doi_10_1016_j_ejca_2022_04_018 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-07-01 |
| PublicationDateYYYYMMDD | 2022-07-01 |
| PublicationDate_xml | – month: 07 year: 2022 text: 2022-07-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Oxford |
| PublicationTitle | European journal of cancer (1990) |
| PublicationTitleAlternate | Eur J Cancer |
| PublicationYear | 2022 |
| Publisher | Elsevier Ltd Elsevier Science Ltd Elsevier |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Science Ltd – name: Elsevier |
| References | Nathan, Cohen, Coupland, Curtis, Damato, Evans (bib199) 2015; 51 Chua, Saxena, Morris (bib53) 2010; 39 Hancock, Wheatley, Harris, Ives, Harrison, Horsman (bib85) 2004; 22 Menzies, Amaria, Rozeman, Huang, Tetzlaff, van de Wiel (bib107) 2021; 27 Konefal, Emami, Pilepich (bib62) 1988; 61 Owen, Shoushtari, Chauhan, Palmieri, Lee, Rohaan (bib203) 2020; 31 Bleehen, Newlands, Lee, Thatcher, Selby, Calvert (bib170) 1995; 13 Robert, Ribas, Schachter, Arance, Grob, Mortier (bib186) 2019; 20 Lienard, Eggermont, Koops, Kroon, Towse, Hiemstra (bib48) 1999; 9 Tawbi, Forsyth, Algazi, Hamid, Hodi, Moschos (bib176) 2018; 379 Marsden, Newton-Bishop, Burrows, Cook, Corrie, Cox (bib10) 2010; 163 Larkin, Hodi, Wolchok (bib139) 2015; 373 Long, Robert, Butler, Couture, Carlino, Day (bib81) 2021; 27 Moehrle, Metzger, Schippert, Garbe, Rassner, Breuninger (bib30) 2003; 29 Kirkwood, Strawderman, Ernstoff, Smith, Borden, Blum (bib92) 1996; 14 Goldinger, Buder-Bakhaya, Lo, Forschner, McKean, Zimmer (bib162) 2021; 162 Chapman, Hauschild, Robert, Haanen, Ascierto, Larkin (bib110) 2011; 364 Grob, Amonkar, Karaszewska, Schachter, Dummer, Mackiewicz (bib142) 2015; 16 Hauschild, Rosien, Lischner (bib3) 2003; 26 Tzellos, Kyrgidis, Mocellin, Chan, Pilati, Apalla (bib19) 2014 Deroose, Eggermont, van Geel, de Wilt, Burger, Verhoef (bib49) 2012; 19 Rauschenberg, Bruns, Brutting, Daubner, Lohaus, Zimmer (bib69) 2019; 110 Ge, Che, Gao, Zhao, Su (bib71) 2021; 31 Lipson, Tawbi, Schadendorf, Ascierto, Matamala, Gutiérrez (bib160) 2021; 39 Burmeister, Henderson, Ainslie, Fisher, Di Iulio, Smithers (bib57) 2012; 13 Davies, Saiag, Robert, Grob, Flaherty, Arance (bib179) 2017; 18 Ny, Jespersen, Karlsson, Alsén, Filges, All-Eriksson (bib202) 2021; 12 Bedikian, DeConti, Conry, Agarwala, Papadopoulos, Kim (bib163) 2011; 22 Katz (bib61) 1981; 7 Zheng, Li, Zhang, Wang, Zhang (bib193) 2020; 10 Onkologie (bib16) 2018 Pehamberger, Soyer, Steiner, Kofler, Binder, Mischer (bib82) 1998; 16 Atkinson, Robert, Grob, Gogas, Dutriaux, Demidov (bib105) 2021; 39 Hodi, O'Day, McDermott, Weber, Sosman, Haanen (bib111) 2010; 363 Haanen, Carbonnel, Robert, Kerr, Peters, Larkin (bib122) 2017; 28 Temple, Arlette (bib32) 2006; 94 Champiat, Lambotte, Barreau, Belkhir, Berdelou, Carbonnel (bib121) 2016; 27 Ascierto, Dréno, Larkin, Ribas, Liszkay, Maio (bib145) 2021 Hauschild, Dummer, Schadendorf, Santinami, Atkinson, Mandala (bib106) 2018 Leiter, Stadler, Mauch, Hohenberger, Brockmeyer, Berking (bib42) 2016; 17 Andtbacka, Collichio, Harrington, Middleton, Downey, Ӧhrling (bib159) 2019; 7 Larkin, Chiarion-Sileni, Gonzalez, Grob, Rutkowski, Lao (bib131) 2019; 381 Nenclares, Ap Dafydd, Bagwan, Begg, Kerawala, King (bib196) 2020; 138 Grob, Dreno, de la Salmoniere, Delaunay, Cupissol, Guillot (bib89) 1998; 351 Henderson, Burmeister, Ainslie, Fisher, Di Iulio, Smithers (bib58) 2015; 16 Robert, Grob, Stroyakovskiy, Karaszewska, Hauschild, Levchenko (bib141) 2019; 381 Bedikian, Millward, Pehamberger, Conry, Gore, Trefzer (bib165) 2006; 24 Lala, Li, Sinha, de Alwis, Chartash, Jain (bib128) 2018; 36 Tio, van der Woude, Prinsen, Jansma, Hoekzema, van Montfrans (bib23) 2017; 31 Larkin, Ascierto, Dreno, Atkinson, Liszkay, Maio (bib151) 2014; 371 Morton, Thompson (bib114) 2007 Faries, Thompson, Cochran, Andtbacka, Mozzillo, Zager (bib37) 2017; 376 Rao, Holtan, Ingle, Croghan, Kottschade, Creagan (bib173) 2006; 106 Rate, Solin, Turrisi (bib60) 1988; 15 Ugurel, Röhmel, Ascierto, Becker, Flaherty, Grob (bib155) 2020; 130 Torphy, Friedman, Ho, Leonard, Thieu, Lewis (bib45) 2021; 29 Sanki, Scolyer, Thompson (bib52) 2009; 35 Cascinelli, Belli, MacKie, Santinami, Bufalino, Morabito (bib86) 2001; 358 Hilke, Sinnberg, Gschwind, Niessner, Demidov, Amaral (bib191) 2020; 12 Negrier, Saiag, Guillot, Verola, Avril, Bailly (bib9) 2005; 132 Rozeman, Menzies, van Akkooi, Adhikari, Bierman, van de Wiel (bib108) 2019; 20 Long, Tykodi, Schneider, Garbe, Gravis, Rashford (bib127) 2018; 29 Lebbe, Meyer, Mortier, Marquez-Rodas, Robert, Rutkowski (bib135) 2021; 39 Ascierto, Del Vecchio, Mandalá, Gogas, Arance, Dalle (bib97) 2020; 21 Leiter, Stadler, Mauch, Hohenberger, Brockmeyer, Berking (bib43) 2019 Arance, Cruz-Merino, Petrella, Jamal, Ny, Carneiro (bib190) 2021; 39 Ribas, Gonzalez, Pavlick, Hamid, Gajewski, Daud (bib152) 2014; 15 Long, Hauschild, Santinami, Atkinson, Mandala, Chiarion-Sileni (bib77) 2017; 377 Robert, Karaszewska, Schachter, Rutkowski, Mackiewicz, Stroiakovski (bib149) 2015; 372 Hamid, Robert, Daud, Hodi, Hwu, Kefford (bib126) 2019; 30 Gogas, Ribas, Chesney, Long, Kirkwood, Dummer (bib158) 2021; 32 Eggermont CUB, Mandala, Long, Victoria Atkinson, Dalle, Haydon (bib100) 2020; 31 Olivier, Schild, Morris, Brown, Markovic (bib59) 2007; 110 Robert, Long, Brady, Dutriaux, Maio, Mortier (bib124) 2014; 372 Wong, Faries, Kennedy, Agarwala, Akhurst, Ariyan (bib38) 2018; 36 Long, Trefzer, Davies, Kefford, Ascierto, Chapman (bib119) 2012; 13 Topalian, Hodi, Brahmer, Gettinger, Smith, McDermott (bib137) 2012; 366 Pires da Silva, Ahmed, Reijers, Weppler, Betof Warner, Patrinely (bib187) 2021; 22 Robert, Thomas, Bondarenko, O'Day, Weber, Garbe (bib120) 2011; 364 Dummer, Schadendorf, Ascierto, Arance, Dutriaux, Di Giacomo (bib148) 2017; 18 Greger, Eastman, Zhang, Bleam, Hughes, Smitheman (bib117) 2012; 11 Petersen, Hanish, Haney, Miller, Burfeind, Tyler (bib51) 2007; 133 Robert, Schachter, Long, Arance, Grob, Mortier (bib138) 2015; 372 Morton, Thompson, Cochran, Mozzillo, Elashoff, Essner (bib40) 2006; 355 Galli, Cavalieri, Di Guardo, Cimminiello, Nichetti, Corti (bib183) 2019; 42 Mornex, Thomas, Mohr, Hauschild, Delaunay, Lesimple (bib172) 2003; 13 Churilla, Chowdhury, Handorf, Collette, Collette, Dong (bib181) 2019; 5 Chiarion Sileni, Nortilli, Aversa, Paccagnella, Medici, Corti (bib168) 2001; 11 Pflugfelder, Kochs, Blum, Capellaro, Czeschik, Dettenborn (bib17) 2013; 11 Verschraegen, Kleeberg, Mulder, Rumke, Truchetet, Czarnetzki (bib174) 1988; 62 Rosenberg, Restifo (bib188) 2015; 348 Ascierto, Mandala, Ferrucci, Rutkowski, Guidoboni, Arance Fernandez (bib156) 2021; 32 Eggermont, Spatz, Robert (bib1) 2014; 383 Ringborg, Rudenstam, Hansson, Hafstrom, Stenstam, Strander (bib167) 1989; 6 Margolin, Ernstoff, Hamid, Lawrence, McDermott, Puzanov (bib175) 2012; 13 Morton, Thompson, Cochran, Mozzillo, Nieweg, Roses (bib41) 2014; 370 Grimaldi, Simeone, Giannarelli, Muto, Falivene, Borzillo (bib66) 2014; 3 Kirova, Chen, Rabarijaona, Piedbois, Le Bourgeois (bib63) 1999; 9 Lallas, Moscarella, Kittler, Longo, Thomas, Zalaudek (bib25) 2021; 185 Wolchok, Chiarion-Sileni, Gonzalez, Grob, Rutkowski, Lao (bib132) 2021; 39 Gershenwald, Scolyer, Hess, Sondak, Long, Ross (bib34) 2017; 67 Teixido, Castillo, Martinez-Vila, Arance, Alos (bib195) 2021; 10 Farshad, Burg, Panizzon, Dummer (bib56) 2002; 146 Jacquillat, Khayat, Banzet, Weil, Avril, Fumoleau (bib171) 1990; 25 Cordeiro, Gervais, Shah, Look Hong, Wright (bib39) 2016; 23 Shoushtari, Wagstaff, Ascierto, Butler, Lao, Marquez-Rodas (bib198) 2020; 38 Pflugfelder, Weide, Eigentler, Forschner, Leiter, Held (bib5) 2010; 28 Ahmadi, Das, Hajarizadeh, Mathy (bib6) 2021; 28 Luke PR, Queirolo, Del Vecchio, Mackiewicz, Chiarion Sileni, de la Cruz Merino (bib79) 2021; 32 Amaral, Kiecker, Schaefer, Stege, Kaehler, Terheyden (bib182) 2020; 8 Maio, Lewis, Demidov, Mandala, Bondarenko, Ascierto (bib103) 2018; 19 Hodi, Chiarion-Sileni, Gonzalez, Grob, Rutkowski, Cowey (bib125) 2018; 19 Marquez-Rodas, Arance, Berciano Guerrero, Díaz Beveridge, Alamo, Garcia Castaño (bib185) 2021; 32 Zimmer, Livingstone, Hassel, Fluck, Eigentler, Loquai (bib80) 2020; 395 Schadendorf, Hodi, Robert, Weber, Margolin, Hamid (bib123) 2015; 33 Long, Stroyakovsky, Gogas, Levchenko, de Braud, Larkin (bib150) 2014; 32 Heppt, Amaral, Kähler, Heinzerling, Hassel, Meissner (bib200) 2019; 7 Morton, Wen, Wong, Economou, Cagle, Storm (bib33) 1992; 127 Nathan, Hassel, Rutkowski, Baurain, Butler, Schlaak (bib201) 2021; 385 Falchook, Long, Kurzrock, Kim, Arkenau, Brown (bib118) 2012; 379 Lala, Li, de Alwis, Sinha, Mayawala, Yamamoto (bib130) 2020; 131 Hauschild, Dummer, Santinami, Atkinson, Mandalà, Kirkwood (bib104) 2020; 38 Creagan, Dalton, Ahmann, Jung, Morton, Langdon (bib93) 1995; 13 Ascierto, Dummer, Gogas, Flaherty, Arance, Mandala (bib144) 2020; 126 Dummer, Ascierto, Gogas, Arance, Mandalà, Liszkay (bib153) 2018; 36 Lebbé, Meyer, Mortier, Marquez-Rodas, Robert, Rutkowski (bib133) 2019; 37 Sosman, Kim, Schuchter, Gonzalez, Pavlick, Weber (bib116) 2012; 366 Chesney, Larkin, Kirkwood, Weber, Khushalani, Lewis (bib189) 2021; 81 Brown, Ballman, Cerhan, Anderson, Carrero, Whitton (bib73) 2017; 18 Dummer, Arenberger, Ascierto, De Groot, Hallmeyer, Lotem (bib154) 2014; 25 Hanna, Lo, Saw (bib15) 2021; 47 Eggermont, Chiarion-Sileni, Grob, Dummer, Wolchok, Schmidt (bib75) 2015; 16 Eggermont, Suciu, Santinami, Testori, Kruit, Marsden (bib94) 2008; 372 Wasif, Bagaria, Ray, Morton (bib54) 2011; 104 (bib8) 2008 Morton, Cochran, Thompson, Elashoff, Essner, Glass (bib36) 2005; 242 Wolchok, Chiarion-Sileni, Gonzalez, Rutkowski, Grob, Cowey (bib136) 2017; 377 Amaria, Postow, Tetzlaff, Ross, Glitza, McQuade (bib109) 2021; 39 Yelamos, Cordova, Blank, Kose, Dusza, Lee (bib29) 2017; 153 Versluis AMH, Weppler, Brown, de Joode, Suijkerbuijk, Zimmer (bib204) 2020; 31 Gillgren, Drzewiecki, Niin, Gullestad, Hellborg, Mansson-Brahme (bib14) 2011; 378 Hilari, Llorca, Traves, Villanueva, Serra-Guillen, Requena (bib21) 2012; 103 Weide, Elsasser, Buttner, Pflugfelder, Leiter, Eigentler (bib50) 2012; 107 Garbe, Radny, Linse, Dummer, Gutzmer, Ulrich (bib83) 2008; 19 Eggermont, Blank, Mandalà, Long, Atkinson, Dalle (bib99) 2020; 38 Hansson, Aamdal, Bastholt, Brandberg, Hernberg, Nilsson (bib90) 2011; 12 Andtbacka, Kaufman, Collichio, Amatruda, Senzer, Chesney (bib47) 2015; 33 Gonzalez, Hong, Carlino, Atkinson, Wang, Lo (bib184) 2019; 37 Weber, Mandala, Del Vecchio, Gogas, Arance, Cowey (bib76) 2017; 377 Mahoney, Joseph, Temple (bib27) 2008; 61 Schadendorf, van Akkooi, Berking, Griewank, Gutzmer, Hauschild (bib112) 2018; 392 Dummer, Ascierto, Gogas, Arance, Mandala, Liszkay (bib143) 2018; 19 Cho, Cust, Foo, Long Olivier (10.1016/j.ejca.2022.04.018_bib59) 2007; 110 Eggermont (10.1016/j.ejca.2022.04.018_bib101) 2021; 39 Thompson (10.1016/j.ejca.2022.04.018_bib35) 2007; 16 Grob (10.1016/j.ejca.2022.04.018_bib89) 1998; 351 Long (10.1016/j.ejca.2022.04.018_bib178) 2021; 39 Ascierto (10.1016/j.ejca.2022.04.018_bib144) 2020; 126 Pehamberger (10.1016/j.ejca.2022.04.018_bib82) 1998; 16 Kirkwood (10.1016/j.ejca.2022.04.018_bib92) 1996; 14 Schadendorf (10.1016/j.ejca.2022.04.018_bib112) 2018; 392 Leiter (10.1016/j.ejca.2022.04.018_bib42) 2016; 17 Tio (10.1016/j.ejca.2022.04.018_bib23) 2017; 31 Ascierto (10.1016/j.ejca.2022.04.018_bib145) 2021 Marsden (10.1016/j.ejca.2022.04.018_bib10) 2010; 163 Zheng (10.1016/j.ejca.2022.04.018_bib193) 2020; 10 Temple (10.1016/j.ejca.2022.04.018_bib32) 2006; 94 Atkinson (10.1016/j.ejca.2022.04.018_bib105) 2021; 39 Burmeister (10.1016/j.ejca.2022.04.018_bib57) 2012; 13 Morton (10.1016/j.ejca.2022.04.018_bib33) 1992; 127 Wheatley (10.1016/j.ejca.2022.04.018_bib13) 2016; 42 Ascierto (10.1016/j.ejca.2022.04.018_bib156) 2021; 32 Mornex (10.1016/j.ejca.2022.04.018_bib172) 2003; 13 Nathan (10.1016/j.ejca.2022.04.018_bib201) 2021; 385 Wolchok (10.1016/j.ejca.2022.04.018_bib136) 2017; 377 Ahmadi (10.1016/j.ejca.2022.04.018_bib6) 2021; 28 Chiarion Sileni (10.1016/j.ejca.2022.04.018_bib168) 2001; 11 Heppt (10.1016/j.ejca.2022.04.018_bib200) 2019; 7 Kleeberg (10.1016/j.ejca.2022.04.018_bib84) 2004; 40 Davies (10.1016/j.ejca.2022.04.018_bib179) 2017; 18 Schadendorf (10.1016/j.ejca.2022.04.018_bib123) 2015; 33 Jacquillat (10.1016/j.ejca.2022.04.018_bib171) 1990; 25 Owen (10.1016/j.ejca.2022.04.018_bib203) 2020; 31 Guo (10.1016/j.ejca.2022.04.018_bib147) 2011; 29 Wong (10.1016/j.ejca.2022.04.018_bib38) 2018; 36 Balch (10.1016/j.ejca.2022.04.018_bib95) 2009; 27 Shoushtari (10.1016/j.ejca.2022.04.018_bib198) 2020; 38 Kirkwood (10.1016/j.ejca.2022.04.018_bib88) 2000; 18 Smith (10.1016/j.ejca.2022.04.018_bib197) 2020; 135 Galli (10.1016/j.ejca.2022.04.018_bib183) 2019; 42 Hodi (10.1016/j.ejca.2022.04.018_bib125) 2018; 19 Falchook (10.1016/j.ejca.2022.04.018_bib118) 2012; 379 Grimaldi (10.1016/j.ejca.2022.04.018_bib66) 2014; 3 Farrow (10.1016/j.ejca.2022.04.018_bib44) 2020; 27 Sosman (10.1016/j.ejca.2022.04.018_bib116) 2012; 366 Atkins (10.1016/j.ejca.2022.04.018_bib157) 2021; 39 Ny (10.1016/j.ejca.2022.04.018_bib202) 2021; 12 Robert (10.1016/j.ejca.2022.04.018_bib120) 2011; 364 Teixido (10.1016/j.ejca.2022.04.018_bib195) 2021; 10 Hauschild (10.1016/j.ejca.2022.04.018_bib106) 2018 Ribas (10.1016/j.ejca.2022.04.018_bib152) 2014; 15 Freshwater (10.1016/j.ejca.2022.04.018_bib129) 2017; 5 Dummer (10.1016/j.ejca.2022.04.018_bib148) 2017; 18 Andtbacka (10.1016/j.ejca.2022.04.018_bib159) 2019; 7 Eggermont CUB (10.1016/j.ejca.2022.04.018_bib100) 2020; 31 Weber (10.1016/j.ejca.2022.04.018_bib76) 2017; 377 Grob (10.1016/j.ejca.2022.04.018_bib142) 2015; 16 Swetter (10.1016/j.ejca.2022.04.018_bib24) 2015; 72 Mahoney (10.1016/j.ejca.2022.04.018_bib27) 2008; 61 Eggermont (10.1016/j.ejca.2022.04.018_bib99) 2020; 38 Tagliaferri (10.1016/j.ejca.2022.04.018_bib70) 2021 Luke PR (10.1016/j.ejca.2022.04.018_bib79) 2021; 32 Larkin (10.1016/j.ejca.2022.04.018_bib131) 2019; 381 Nenclares (10.1016/j.ejca.2022.04.018_bib196) 2020; 138 Amaral (10.1016/j.ejca.2022.04.018_bib113) 2020; 12 Robert (10.1016/j.ejca.2022.04.018_bib141) 2019; 381 Weide (10.1016/j.ejca.2022.04.018_bib50) 2012; 107 Greger (10.1016/j.ejca.2022.04.018_bib117) 2012; 11 Long (10.1016/j.ejca.2022.04.018_bib102) 2021 Middleton (10.1016/j.ejca.2022.04.018_bib166) 2000; 18 Amaral (10.1016/j.ejca.2022.04.018_bib182) 2020; 8 Pflugfelder (10.1016/j.ejca.2022.04.018_bib17) 2013; 11 Bedikian (10.1016/j.ejca.2022.04.018_bib163) 2011; 22 Young (10.1016/j.ejca.2022.04.018_bib169) 2001; 13 Henderson (10.1016/j.ejca.2022.04.018_bib58) 2015; 16 Robert (10.1016/j.ejca.2022.04.018_bib186) 2019; 20 Wasif (10.1016/j.ejca.2022.04.018_bib54) 2011; 104 Arance (10.1016/j.ejca.2022.04.018_bib190) 2021; 39 Sanki (10.1016/j.ejca.2022.04.018_bib52) 2009; 35 Eggermont (10.1016/j.ejca.2022.04.018_bib1) 2014; 383 Eggermont (10.1016/j.ejca.2022.04.018_bib96) 2019; 119 Hayes (10.1016/j.ejca.2022.04.018_bib12) 2016; 17 Eggermont (10.1016/j.ejca.2022.04.018_bib98) 2018; 378 Larkin (10.1016/j.ejca.2022.04.018_bib151) 2014; 371 Hanna (10.1016/j.ejca.2022.04.018_bib15) 2021; 47 Marquez-Rodas (10.1016/j.ejca.2022.04.018_bib185) 2021; 32 Coit (10.1016/j.ejca.2022.04.018_bib7) 2009; 7 Gillgren (10.1016/j.ejca.2022.04.018_bib14) 2011; 378 Lebbe (10.1016/j.ejca.2022.04.018_bib135) 2021; 39 Long (10.1016/j.ejca.2022.04.018_bib119) 2012; 13 Dummer (10.1016/j.ejca.2022.04.018_bib146) 2021; 39 Dummer (10.1016/j.ejca.2022.04.018_bib154) 2014; 25 Negrier (10.1016/j.ejca.2022.04.018_bib9) 2005; 132 Cho (10.1016/j.ejca.2022.04.018_bib192) 2021; 31 Ko (10.1016/j.ejca.2022.04.018_bib115) 2011; 223 Onkologie (10.1016/j.ejca.2022.04.018_bib16) 2018 Garsa (10.1016/j.ejca.2022.04.018_bib72) 2021; 11 Rozeman (10.1016/j.ejca.2022.04.018_bib108) 2019; 20 Topalian (10.1016/j.ejca.2022.04.018_bib137) 2012; 366 Gershenwald (10.1016/j.ejca.2022.04.018_bib34) 2017; 67 Saiag (10.1016/j.ejca.2022.04.018_bib2) 2007; 17 Goldinger (10.1016/j.ejca.2022.04.018_bib162) 2021; 162 Larkin (10.1016/j.ejca.2022.04.018_bib139) 2015; 373 Amaria (10.1016/j.ejca.2022.04.018_bib109) 2021; 39 Breuninger (10.1016/j.ejca.2022.04.018_bib31) 1999; 23 Hodi (10.1016/j.ejca.2022.04.018_bib111) 2010; 363 Tzellos (10.1016/j.ejca.2022.04.018_bib19) 2014 Robert (10.1016/j.ejca.2022.04.018_bib124) 2014; 372 10.1016/j.ejca.2022.04.018_bib65 Torphy (10.1016/j.ejca.2022.04.018_bib45) 2021; 29 Farshad (10.1016/j.ejca.2022.04.018_bib56) 2002; 146 Morton (10.1016/j.ejca.2022.04.018_bib114) 2007 Long (10.1016/j.ejca.2022.04.018_bib127) 2018; 29 Moschos (10.1016/j.ejca.2022.04.018_bib55) 2006; 24 Morton (10.1016/j.ejca.2022.04.018_bib40) 2006; 355 Kirova (10.1016/j.ejca.2022.04.018_bib63) 1999; 9 Garbe (10.1016/j.ejca.2022.04.018_bib11) 2008; 18 Eggermont (10.1016/j.ejca.2022.04.018_bib75) 2015; 16 Long (10.1016/j.ejca.2022.04.018_bib150) 2014; 32 Hodi HAT (10.1016/j.ejca.2022.04.018_bib161) 2021; 32 Hamid (10.1016/j.ejca.2022.04.018_bib126) 2019; 30 Moehrle (10.1016/j.ejca.2022.04.018_bib30) 2003; 29 Long (10.1016/j.ejca.2022.04.018_bib81) 2021; 27 Katz (10.1016/j.ejca.2022.04.018_bib61) 1981; 7 Gonzalez (10.1016/j.ejca.2022.04.018_bib184) 2019; 37 Lala (10.1016/j.ejca.2022.04.018_bib128) 2018; 36 Maio (10.1016/j.ejca.2022.04.018_bib103) 2018; 19 Andtbacka (10.1016/j.ejca.2022.04.018_bib47) 2015; 33 Versluis AMH (10.1016/j.ejca.2022.04.018_bib204) 2020; 31 Leiter (10.1016/j.ejca.2022.04.018_bib43) 2019 Lebbé (10.1016/j.ejca.2022.04.018_bib133) 2019; 37 Gogas (10.1016/j.ejca.2022.04.018_bib158) 2021; 32 Morton (10.1016/j.ejca.2022.04.018_bib41) 2014; 370 Mahajan (10.1016/j.ejca.2022.04.018_bib74) 2017; 18 Chua (10.1016/j.ejca.2022.04.018_bib53) 2010; 39 Creagan (10.1016/j.ejca.2022.04.018_bib93) 1995; 13 Ascierto (10.1016/j.ejca.2022.04.018_bib140) 2016; 17 Eggermont (10.1016/j.ejca.2022.04.018_bib94) 2008; 372 Hauschild (10.1016/j.ejca.2022.04.018_bib3) 2003; 26 Dummer (10.1016/j.ejca.2022.04.018_bib143) 2018; 19 Rao (10.1016/j.ejca.2022.04.018_bib173) 2006; 106 Margolin HAT (10.1016/j.ejca.2022.04.018_bib177) 2021; 32 Lebbé (10.1016/j.ejca.2022.04.018_bib134) 2018; 29 Ringborg (10.1016/j.ejca.2022.04.018_bib167) 1989; 6 Rate (10.1016/j.ejca.2022.04.018_bib60) 1988; 15 Petersen (10.1016/j.ejca.2022.04.018_bib51) 2007; 133 Yelamos (10.1016/j.ejca.2022.04.018_bib29) 2017; 153 Morton (10.1016/j.ejca.2022.04.018_bib46) 1991; 214 Zimmer (10.1016/j.ejca.2022.04.018_bib80) 2020; 395 Ascierto (10.1016/j.ejca.2022.04.018_bib97) 2020; 21 Krausz (10.1016/j.ejca.2022.04.018_bib22) 2021; 47 Long (10.1016/j.ejca.2022.04.018_bib64) 2018; 19 Champiat (10.1016/j.ejca.2022.04.018_bib121) 2016; 27 Churilla (10.1016/j.ejca.2022.04.018_bib181) 2019; 5 Eggermont (10.1016/j.ejca.2022.04.018_bib91) 2005; 366 Haanen (10.1016/j.ejca.2022.04.018_bib122) 2017; 28 Lala (10.1016/j.ejca.2022.04.018_bib130) 2020; 131 Lipson (10.1016/j.ejca.2022.04.018_bib160) 2021; 39 Tawbi (10.1016/j.ejca.2022.04.018_bib176) 2018; 379 Deroose (10.1016/j.ejca.2022.04.018_bib49) 2012; 19 Gaiser (10.1016/j.ejca.2022.04.018_bib194) 2017; 12 Ge (10.1016/j.ejca.2022.04.018_bib71) 2021; 31 Hilari (10.1016/j.ejca.2022.04.018_bib21) 2012; 103 Cascinelli (10.1016/j.ejca.2022.04.018_bib86) 2001; 358 Chapman (10.1016/j.ejca.2022.04.018_bib110) 2011; 364 Cotter (10.1016/j.ejca.2022.04.018_bib28) 2008; 34 Pflugfelder (10.1016/j.ejca.2022.04.018_bib5) 2010; 28 Hauschild (10.1016/j.ejca.2022.04.018_bib104) 2020; 38 Robert (10.1016/j.ejca.2022.04.018_bib149) 2015; 372 Konefal (10.1016/j.ejca.2022.04.018_bib62) 1988; 61 Rosenberg (10.1016/j.ejca.2022.04.018_bib188) 2015; 348 Eggermont (10.1016/j.ejca.2022.04.018_bib78) 2016; 375 Faries (10.1016/j.ejca.2022.04.018_bib37) 2017; 376 Cordeiro (10.1016/j.ejca.2022.04.018_bib39) 2016; 23 de Vries (10.1016/j.ejca.2022.04.018_bib20) 2016; 174 Buettiker (10.1016/j.ejca.2022.04.018_bib26) 2008; 144 Robert (10.1016/j.ejca.2022.04.018_bib138) 2015; 372 Hancock (10.1016/j.ejca.2022.04.018_bib85) 2004; 22 Dummer (10.1016/j.ejca.2022.04.018_bib153) 2018; 36 Hilke (10.1016/j.ejca.2022.04.018_bib191) 2020; 12 Menzies (10.1016/j.ejca.2022.04.018_bib107) 2021; 27 Pires da Silva (10.1016/j.ejca.2022.04.018_bib187) 2021; 22 Brown (10.1016/j.ejca.2022.04.018_bib73) 2017; 18 Patel (10.1016/j.ejca.2022.04.018_bib164) 2011; 47 Verschraegen (10.1016/j.ejca.2022.04.018_bib174) 1988; 62 Margolin (10.1016/j.ejca.2022.04.018_bib175) 2012; 13 Ugurel (10.1016/j.ejca.2022.04.018_bib155) 2020; 130 Lienard (10.1016/j.ejca.2022.04.018_bib48) 1999; 9 Rauschenberg (10.1016/j.ejca.2022.04.018_bib69) 2019; 110 Crittenden (10.1016/j.ejca.2022.04.018_bib67) 2015; 25 Lehrer (10.1016/j.ejca.2022.04.018_bib68) 2019; 130 Long (10.1016/j.ejca.2022.04.018_bib77) 2017; 377 Hansson (10.1016/j.ejca.2022.04.018_bib90) 2011; 12 Bleehen (10.1016/j.ejca.2022.04.018_bib170) 1995; 13 Chesney (10.1016/j.ejca.2022.04.018_bib189) 2021; 81 Gaudy-Marqueste (10.1016/j.ejca.2022.04.018_bib180) 2014; 25 Martin (10.1016/j.ejca.2022.04.018_b |
| References_xml | – volume: 12 start-page: 5155 year: 2021 ident: bib202 article-title: The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma publication-title: Nat Commun – year: 2008 ident: bib8 article-title: Australian cancer network melanoma guidelines revision working party publication-title: Clinical practice guidelines for the management of melanoma in Australia and New Zealand – volume: 372 start-page: 320 year: 2014 end-page: 330 ident: bib124 article-title: Nivolumab in previously untreated melanoma without BRAF mutation publication-title: N Engl J Med – volume: 32 start-page: S1283 year: 2021 end-page: S1346 ident: bib79 article-title: LBA3 PR - pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: efficacy and safety results from the KEYNOTE-716 double-blind phase III trial publication-title: Ann Oncol – volume: 35 start-page: 313 year: 2009 end-page: 319 ident: bib52 article-title: Surgery for melanoma metastases of the gastrointestinal tract: indications and results publication-title: Eur J Surg Oncol – volume: 25 start-page: iv392 year: 2014 ident: bib154 article-title: 1130TiP- NEMO: a phase 3 trial OF binimetinib (MEK162) versus dacarbazine IN patients with advanced NRAS-mutant melanoma who are untreated or have progressed after any number of immunotherapy regimens publication-title: Ann Oncol – volume: 29 start-page: 2208 year: 2018 end-page: 2213 ident: bib127 article-title: Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer publication-title: Ann Oncol – volume: 104 start-page: 111 year: 2011 end-page: 115 ident: bib54 article-title: Does metastasectomy improve survival in patients with Stage IV melanoma? A cancer registry analysis of outcomes publication-title: J Surg Oncol – volume: 24 start-page: 3164 year: 2006 end-page: 3171 ident: bib55 article-title: Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses publication-title: J Clin Oncol – volume: 372 start-page: 2521 year: 2015 end-page: 2532 ident: bib138 article-title: Pembrolizumab versus ipilimumab in advanced melanoma publication-title: N Engl J Med – volume: 72 start-page: 1047 year: 2015 end-page: 1053 ident: bib24 article-title: Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type publication-title: J Am Acad Dermatol – volume: 13 start-page: 97 year: 2003 end-page: 103 ident: bib172 article-title: A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma publication-title: Melanoma Res – volume: 371 start-page: 1867 year: 2014 end-page: 1876 ident: bib151 article-title: Combined vemurafenib and cobimetinib in BRAF-mutated melanoma publication-title: N Engl J Med – volume: 383 start-page: 816 year: 2014 end-page: 827 ident: bib1 article-title: Cutaneous melanoma publication-title: Lancet – volume: 25 start-page: 2086 year: 2014 end-page: 2091 ident: bib180 article-title: On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases publication-title: Ann Oncol – volume: 19 start-page: 603 year: 2018 end-page: 615 ident: bib143 article-title: Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial publication-title: Lancet Oncol – volume: 379 start-page: 1893 year: 2012 end-page: 1901 ident: bib118 article-title: Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial publication-title: Lancet – volume: 11 start-page: 354 year: 2021 end-page: 365 ident: bib72 article-title: Radiation therapy for brain metastases: a systematic review publication-title: Practical radiation oncology – volume: 372 start-page: 117 year: 2008 end-page: 126 ident: bib94 article-title: Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial publication-title: Lancet (London, England) – volume: 28 start-page: 316 year: 2010 end-page: 318 ident: bib5 article-title: Incisional biopsy and melanoma prognosis: Facts and controversies publication-title: Clin Dermatol – volume: 110 start-page: 1791 year: 2007 end-page: 1795 ident: bib59 article-title: A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma publication-title: Cancer – volume: 19 start-page: 1480 year: 2018 end-page: 1492 ident: bib125 article-title: Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial publication-title: Lancet Oncol – volume: 16 start-page: 35 year: 2007 end-page: 54 ident: bib35 article-title: Sentinel node mapping for melanoma: results of trials and current applications publication-title: Surg Oncol Clin – volume: 20 start-page: 948 year: 2019 end-page: 960 ident: bib108 article-title: Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial publication-title: Lancet Oncol – volume: 39 start-page: 9500 year: 2021 ident: bib101 article-title: Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma publication-title: J Clin Oncol – volume: 27 start-page: 6199 year: 2009 end-page: 6206 ident: bib95 article-title: Final version of 2009 AJCC melanoma staging and classification publication-title: J Clin Oncol – volume: 154 start-page: 453 year: 2006 end-page: 459 ident: bib18 article-title: Conventional histology vs. three-dimensional histology in lentigo maligna melanoma publication-title: Br J Dermatol – volume: 36 start-page: 9504 year: 2018 ident: bib153 article-title: Overall survival in COLUMBUS: a phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma publication-title: J Clin Oncol – volume: 31 start-page: 1075 year: 2020 end-page: 1082 ident: bib203 article-title: Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy publication-title: Ann Oncol – volume: 3 year: 2014 ident: bib66 article-title: Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy publication-title: OncoImmunology – volume: 32 start-page: S867 year: 2021 end-page: S905 ident: bib161 article-title: 1036O - relatlimab (RELA) + nivolumab (NIVO) vs. NIVO in previously untreated metastatic or unresectable melanoma: additional efficacy in RELATIVITY-047 publication-title: Ann Oncol – volume: 47 start-page: 1539 year: 2021 end-page: 1544 ident: bib22 article-title: Systematic review of technical variations for Mohs micrographic surgery for melanoma publication-title: Dermatol Surg – volume: 39 start-page: 9516 year: 2021 ident: bib135 article-title: Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: three-year results of CheckMate 511 publication-title: J Clin Oncol – volume: 174 start-page: 588 year: 2016 end-page: 593 ident: bib20 article-title: Recurrence rate of lentigo maligna after micrographically controlled staged surgical excision publication-title: Br J Dermatol – volume: 81 start-page: CT008 year: 2021 ident: bib189 article-title: Abstract CT008: lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced (unresectable or metastatic) melanoma: durable duration of response at 28 month follow up publication-title: Cancer Res – volume: 13 start-page: 458 year: 2001 end-page: 465 ident: bib169 article-title: Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma publication-title: Clin Oncol – volume: 21 start-page: 1465 year: 2020 end-page: 1477 ident: bib97 article-title: Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial publication-title: Lancet Oncol – volume: 42 start-page: 73 year: 2016 end-page: 81 ident: bib13 article-title: Surgical excision margins in primary cutaneous melanoma: a meta-analysis and Bayesian probability evaluation publication-title: Cancer Treat Rev – volume: 107 start-page: 422 year: 2012 end-page: 428 ident: bib50 article-title: Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis publication-title: British journal of cancer – volume: 27 start-page: 5280 year: 2021 ident: bib81 article-title: Standard-dose pembrolizumab plus alternate-dose ipilimumab in advanced melanoma: KEYNOTE-029 cohort 1C, a phase 2 randomized study of two dosing schedules publication-title: Clin Cancer Res – year: 2019 ident: bib43 article-title: Final analysis of DeCOG-SLT trial: No survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node publication-title: J Clin Oncol – volume: 12 year: 2020 ident: bib191 article-title: Distinct mutation patterns reveal melanoma subtypes and influence immunotherapy response in advanced melanoma patients publication-title: Cancers – volume: 18 start-page: 1049 year: 2017 end-page: 1060 ident: bib73 article-title: Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial publication-title: Lancet Oncol – volume: 61 start-page: 243 year: 1988 end-page: 246 ident: bib62 article-title: Analysis of dose fractionation in the palliation of metastases from malignant melanoma publication-title: Cancer – volume: 27 start-page: 5121 year: 2020 end-page: 5125 ident: bib44 article-title: Adjuvant therapy is effective for melanoma patients with a positive sentinel lymph node biopsy who Forego completion lymphadenectomy publication-title: Ann Surg Oncol – volume: 39 start-page: 9525 year: 2021 ident: bib105 article-title: Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event (AE) management algorithm in patients (pts) treated with adjuvant dabrafenib + trametinib (dab + tram): primary results of COMBI-APlus publication-title: J Clin Oncol – volume: 29 start-page: 2904 year: 2011 end-page: 2909 ident: bib147 article-title: Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification publication-title: J Clin Oncol – volume: 17 start-page: 757 year: 2016 end-page: 767 ident: bib42 article-title: Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial publication-title: Lancet Oncol – volume: 37 start-page: 867 year: 2019 end-page: 875 ident: bib133 article-title: Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb/IV CheckMate 511 trial publication-title: J Clin Oncol – volume: 7 start-page: 907 year: 1981 end-page: 911 ident: bib61 article-title: The results of different fractionation schemes in the palliative irradiation of metastatic melanoma publication-title: Int J Radiat Oncol Biol Phys – volume: 381 start-page: 1535 year: 2019 end-page: 1546 ident: bib131 article-title: Five-year survival with combined nivolumab and ipilimumab in advanced melanoma publication-title: N Engl J Med – volume: 10 year: 2021 ident: bib195 article-title: Molecular markers and targets in melanoma publication-title: Cells – volume: 18 start-page: 435 year: 2017 end-page: 445 ident: bib148 article-title: Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial publication-title: Lancet Oncol – volume: 28 start-page: 6168 year: 2021 end-page: 6176 ident: bib6 article-title: Impact of shave biopsy on diagnosis and management of cutaneous melanoma: a systematic review and meta-analysis publication-title: Ann Surg Oncol – volume: 378 start-page: 1789 year: 2018 end-page: 1801 ident: bib98 article-title: Adjuvant pembrolizumab versus placebo in resected stage III melanoma publication-title: N Engl J Med – volume: 163 start-page: 238 year: 2010 end-page: 256 ident: bib10 article-title: Revised U.K. guidelines for the management of cutaneous melanoma 2010 publication-title: Br J Dermatol – volume: 38 start-page: 10001 year: 2020 ident: bib104 article-title: Long-term benefit of adjuvant dabrafenib + trametinib (D+T) in patients (pts) with resected stage III BRAF V600–mutant melanoma: Five-year analysis of COMBI-AD publication-title: J Clin Oncol – volume: 19 start-page: 627 year: 2012 end-page: 635 ident: bib49 article-title: 20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose matters publication-title: Ann Surg Oncol – volume: 190 start-page: 913 year: 2005 end-page: 917 ident: bib4 article-title: Is incisional biopsy of melanoma harmful? publication-title: Am J Surg – volume: 17 start-page: 184 year: 2016 end-page: 192 ident: bib12 article-title: Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial publication-title: Lancet Oncol – volume: 110 start-page: 11 year: 2019 end-page: 20 ident: bib69 article-title: Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases publication-title: Eur J Cancer – volume: 32 start-page: S1283 year: 2021 end-page: S1346 ident: bib156 article-title: LBA40 - SECOMBIT: the best sequential approach with combo immunotherapy ipilimumab (I)/nivolumab (N) and combo target therapy encorafenib (E)/binimetinib (B) in patients with BRAF mutated metastatic melanoma: a phase II randomized study publication-title: Ann Oncol – volume: 84 start-page: 1146 year: 2001 end-page: 1149 ident: bib87 article-title: Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study publication-title: British journal of cancer – volume: 32 start-page: S867 year: 2021 end-page: S905 ident: bib185 article-title: 1038MO - intracranial activity of encorafenib and binimetinib followed by radiotherapy in patients with BRAF mutated melanoma and brain metastasis: preliminary results of the GEM1802/EBRAIN-MEL phase II clinical trial publication-title: Ann Oncol – volume: 31 start-page: 413 year: 2021 end-page: 420 ident: bib71 article-title: Combination of radiotherapy and targeted therapy for melanoma brain metastases: a systematic review publication-title: Melanoma Res – volume: 14 start-page: 7 year: 1996 end-page: 17 ident: bib92 article-title: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684 publication-title: J Clin Oncol – volume: 36 start-page: 399 year: 2018 end-page: 413 ident: bib38 article-title: Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American society of clinical oncology and society of surgical oncology clinical practice guideline update publication-title: J Clin Oncol – volume: 377 start-page: 1345 year: 2017 end-page: 1356 ident: bib136 article-title: Overall survival with combined nivolumab and ipilimumab in advanced melanoma publication-title: N Engl J Med – volume: 132 start-page: S3 year: 2005 end-page: S85 ident: bib9 article-title: Guidelines for clinical practice: standards, options and recommendations 2005 for the management of adult patients exhibiting an M0 cutaneous melanoma, full report. National Federation of cancer campaign centers. French dermatology society. Update of the 1995 consensus conference and the 1998 standards, options, and recommendations publication-title: Annales de dermatologie et de venereologie – volume: 119 start-page: 1 year: 2019 end-page: 10 ident: bib96 article-title: Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial publication-title: Eur J Cancer – volume: 106 start-page: 375 year: 2006 end-page: 382 ident: bib173 article-title: Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma publication-title: Cancer – volume: 61 start-page: 419 year: 2008 end-page: 424 ident: bib27 article-title: Topical imiquimod therapy for lentigo maligna publication-title: Ann Plast Surg – volume: 5 start-page: 243 year: 2019 end-page: 247 ident: bib181 article-title: Comparison of local control of brain metastases with stereotactic radiosurgery vs surgical resection: a secondary analysis of a randomized clinical trial publication-title: JAMA Oncol – volume: 18 start-page: 152 year: 2008 end-page: 160 ident: bib11 article-title: Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting publication-title: Melanoma Res – volume: 12 start-page: 144 year: 2011 end-page: 152 ident: bib90 article-title: Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial publication-title: Lancet Oncol – volume: 16 start-page: 522 year: 2015 end-page: 530 ident: bib75 article-title: Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial publication-title: Lancet Oncol – volume: 366 start-page: 1189 year: 2005 end-page: 1196 ident: bib91 article-title: Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial publication-title: Lancet (London, England) – year: 2021 ident: bib145 article-title: 5-Year outcomes with cobimetinib plus vemurafenib in BRAF (V600) mutation-positive advanced melanoma: extended follow-up of the coBRIM study publication-title: Clin Cancer Res – volume: 131 start-page: 68 year: 2020 end-page: 75 ident: bib130 article-title: A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation publication-title: Eur J Cancer – volume: 377 start-page: 1813 year: 2017 end-page: 1823 ident: bib77 article-title: Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma publication-title: N Engl J Med – volume: 11 start-page: 189 year: 2001 end-page: 196 ident: bib168 article-title: Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients publication-title: Melanoma Res – volume: 7 start-page: 299 year: 2019 ident: bib200 article-title: Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study publication-title: Journal for immunotherapy of cancer – volume: 381 start-page: 626 year: 2019 end-page: 636 ident: bib141 article-title: Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma publication-title: N Engl J Med – volume: 9 start-page: 611 year: 1999 end-page: 613 ident: bib63 article-title: Radiotherapy as palliative treatment for metastatic melanoma publication-title: Melanoma Res – volume: 36 start-page: 3062 year: 2018 ident: bib128 article-title: A six-weekly (Q6W) dosing schedule for pembrolizumab based on an exposure-response (E-R) evaluation using modeling and simulation publication-title: J Clin Oncol – reference: Tawbi H. Safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with advanced melanoma(MEL) metastatic to the brain: Initial Results From Phase 2 CheckMate 204. SMR2016. – volume: 372 start-page: 30 year: 2015 end-page: 39 ident: bib149 article-title: Improved overall survival in melanoma with combined dabrafenib and trametinib publication-title: N Engl J Med – volume: 22 start-page: 53 year: 2004 end-page: 61 ident: bib85 article-title: Adjuvant interferon in high-risk melanoma: the AIM HIGH Study–United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma publication-title: J Clin Oncol – volume: 12 start-page: 1027 year: 2020 ident: bib113 article-title: Primary resistance to PD-1-based immunotherapy-A study in 319 patients with stage IV melanoma publication-title: Cancers – volume: 18 start-page: 2444 year: 2000 end-page: 2458 ident: bib88 article-title: High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190 publication-title: J Clin Oncol – volume: 31 start-page: 616 year: 2017 end-page: 624 ident: bib23 article-title: A systematic review on the role of imiquimod in lentigo maligna and lentigo maligna melanoma: need for standardization of treatment schedule and outcome measures publication-title: J Eur Acad Dermatol Venereol : JEADV – volume: 25 start-page: 263 year: 1990 end-page: 266 ident: bib171 article-title: Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma publication-title: Cancer Chemother Pharmacol – volume: 13 start-page: 1087 year: 2012 end-page: 1095 ident: bib119 article-title: Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial publication-title: Lancet Oncol – volume: 11 start-page: 909 year: 2012 end-page: 920 ident: bib117 article-title: Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations publication-title: Mol Cancer Therapeut – volume: 223 start-page: 241 year: 2011 end-page: 250 ident: bib115 article-title: A new era: melanoma genetics and therapeutics publication-title: J Pathol – volume: 11 start-page: 1 year: 2013 end-page: 116 ident: bib17 article-title: Malignant melanoma S3-guideline “diagnosis, therapy and follow-up of melanoma” publication-title: J Dtsch Dermatol Ges – volume: 138 start-page: 11 year: 2020 end-page: 18 ident: bib196 article-title: Head and neck mucosal melanoma: the United Kingdom national guidelines publication-title: European Journal of Cancer – volume: 29 start-page: 366 year: 2003 end-page: 374 ident: bib30 article-title: “Functional” surgery in subungual melanoma publication-title: Dermatol Surg – volume: 19 start-page: 510 year: 2018 end-page: 520 ident: bib103 article-title: Adjuvant vemurafenib in resected, BRAF(V600) mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial publication-title: Lancet Oncol – volume: 370 start-page: 599 year: 2014 end-page: 609 ident: bib41 article-title: Final trial report of sentinel-node biopsy versus nodal observation in melanoma publication-title: N Engl J Med – volume: 23 start-page: 4178 year: 2016 end-page: 4188 ident: bib39 article-title: Sentinel lymph node biopsy in thin cutaneous melanoma: a systematic review and meta-analysis publication-title: Ann Surg Oncol – volume: 12 year: 2017 ident: bib194 article-title: Variables that influence BRAF mutation probability: a next-generation sequencing, non-interventional investigation of BRAFV600 mutation status in melanoma publication-title: PLoS One – volume: 18 start-page: 1040 year: 2017 end-page: 1048 ident: bib74 article-title: Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial publication-title: Lancet Oncol – volume: 348 start-page: 62 year: 2015 end-page: 68 ident: bib188 article-title: Adoptive cell transfer as personalized immunotherapy for human cancer publication-title: Science (New York, NY) – volume: 39 start-page: 9502 year: 2021 ident: bib109 article-title: Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma publication-title: J Clin Oncol – volume: 32 start-page: S867 year: 2021 end-page: S905 ident: bib158 article-title: 1037O - MASTERKEY-265: a phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL) publication-title: Ann Oncol – volume: 37 year: 2019 ident: bib184 article-title: A phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab plus nivolumab alone in patients with melanoma brain metastases (ABC-X Trial) publication-title: J Clin Oncol – volume: 17 start-page: 1248 year: 2016 end-page: 1260 ident: bib140 article-title: Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial publication-title: Lancet Oncol – volume: 33 start-page: 1889 year: 2015 end-page: 1894 ident: bib123 article-title: Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma publication-title: J Clin Oncol – volume: 395 start-page: 1558 year: 2020 end-page: 1568 ident: bib80 article-title: Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial publication-title: Lancet (London, England) – volume: 364 start-page: 2517 year: 2011 end-page: 2526 ident: bib120 article-title: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma publication-title: N Engl J Med – volume: 39 start-page: 634 year: 2010 end-page: 639 ident: bib53 article-title: Surgical metastasectomy in AJCC stage IV M1c melanoma patients with gastrointestinal and liver metastases publication-title: Ann Acad Med Singapore – start-page: Cd010308 year: 2014 ident: bib19 article-title: Interventions for melanoma in situ, including lentigo maligna publication-title: Cochrane Database Syst Rev – volume: 33 start-page: 2780 year: 2015 end-page: 2788 ident: bib47 article-title: Talimogene laherparepvec improves durable response rate in patients with advanced melanoma publication-title: J Clin Oncol – volume: 7 start-page: 250 year: 2009 end-page: 275 ident: bib7 article-title: Melanoma publication-title: J Natl Compr Cancer Netw : JNCCN. – volume: 392 start-page: 971 year: 2018 end-page: 984 ident: bib112 publication-title: Melanoma. The Lancet. – volume: 19 start-page: 672 year: 2018 end-page: 681 ident: bib64 article-title: Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study publication-title: Lancet Oncol – volume: 32 start-page: 9011 year: 2014 ident: bib150 article-title: COMBI-d: a randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma publication-title: J Clin Oncol – volume: 22 start-page: 836 year: 2021 end-page: 847 ident: bib187 article-title: Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study publication-title: Lancet Oncol – year: 2021 ident: bib102 article-title: Adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in patients with resected stage IIIB-D/IV melanoma (CheckMate 915) publication-title: AACR Annual Meeting – volume: 16 start-page: 1389 year: 2015 end-page: 1398 ident: bib142 article-title: Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial publication-title: Lancet Oncol – volume: 42 start-page: 186 year: 2019 end-page: 194 ident: bib183 article-title: Combination of immunotherapy and brain radiotherapy in metastatic melanoma: a retrospective analysis publication-title: Oncology research and treatment – volume: 40 start-page: 390 year: 2004 end-page: 402 ident: bib84 article-title: Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis publication-title: Eur J Cancer – volume: 67 start-page: 472 year: 2017 end-page: 492 ident: bib34 article-title: Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual publication-title: CA: a cancer journal for clinicians – volume: 130 start-page: 126 year: 2020 end-page: 138 ident: bib155 article-title: Survival of patients with advanced metastatic melanoma: the impact of MAP kinase pathway inhibition and immune checkpoint inhibition - update 2019 publication-title: Eur J Cancer – volume: 135 start-page: 22 year: 2020 end-page: 30 ident: bib197 article-title: Ano-uro-genital mucosal melanoma UK national guidelines publication-title: Eur J Cancer – volume: 127 start-page: 392 year: 1992 end-page: 399 ident: bib33 article-title: Technical details of intraoperative lymphatic mapping for early stage melanoma publication-title: Arch Surg – volume: 31 start-page: S1142 year: 2020 end-page: S1215 ident: bib100 article-title: LBA46 - pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: final results regarding distant metastasis-free survival from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial publication-title: Ann Oncol – volume: 379 start-page: 722 year: 2018 end-page: 730 ident: bib176 article-title: Combined nivolumab and ipilimumab in melanoma metastatic to the brain publication-title: N Engl J Med – volume: 5 start-page: 43 year: 2017 ident: bib129 article-title: Evaluation of dosing strategy for pembrolizumab for oncology indications publication-title: Journal for immunotherapy of cancer – volume: 378 start-page: 1635 year: 2011 end-page: 1642 ident: bib14 article-title: 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial publication-title: Lancet (London, England) – volume: 28 start-page: iv119 year: 2017 end-page: i142 ident: bib122 article-title: Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up publication-title: Ann Oncol – volume: 385 start-page: 1196 year: 2021 end-page: 1206 ident: bib201 article-title: Overall survival benefit with tebentafusp in metastatic uveal melanoma publication-title: N Engl J Med – volume: 366 start-page: 2443 year: 2012 end-page: 2454 ident: bib137 article-title: Safety, activity, and immune correlates of anti–PD-1 antibody in cancer publication-title: N Engl J Med – volume: 34 start-page: 147 year: 2008 end-page: 151 ident: bib28 article-title: Treatment of lentigo maligna with imiquimod before staged excision publication-title: Dermatol Surg – volume: 32 start-page: S867 year: 2021 end-page: S905 ident: bib177 article-title: 1039MO - CheckMate 204: 3-year outcomes of treatment with combination nivolumab (NIVO) plus ipilimumab (IPI) for patients (pts) with active melanoma brain metastases (MBM) publication-title: Ann Oncol – volume: 133 start-page: 104 year: 2007 end-page: 110 ident: bib51 article-title: Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma publication-title: J Thorac Cardiovasc Surg – volume: 103 start-page: 614 year: 2012 end-page: 623 ident: bib21 article-title: Conventional surgery compared with slow Mohs micrographic surgery in the treatment of lentigo maligna: a retrospective study of 62 cases publication-title: Actas Dermo-Sifiliográficas – volume: 18 start-page: 158 year: 2000 end-page: 166 ident: bib166 article-title: Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma publication-title: J Clin Oncol – volume: 24 start-page: 4738 year: 2006 end-page: 4745 ident: bib165 article-title: Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group publication-title: J Clin Oncol – start-page: 8508 year: 2007 ident: bib114 article-title: An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites publication-title: J clinic oncol – volume: 18 start-page: 863 year: 2017 end-page: 873 ident: bib179 article-title: Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial publication-title: Lancet Oncol – volume: 153 start-page: 1278 year: 2017 end-page: 1284 ident: bib29 article-title: Correlation of handheld reflectance confocal microscopy with radial video mosaicing for margin mapping of lentigo maligna and lentigo maligna melanoma publication-title: JAMA dermatology – volume: 13 start-page: 589 year: 2012 end-page: 597 ident: bib57 article-title: Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial publication-title: Lancet Oncol – volume: 30 start-page: 582 year: 2019 end-page: 588 ident: bib126 article-title: Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 publication-title: Ann Oncol – volume: 162 start-page: 22 year: 2021 end-page: 33 ident: bib162 article-title: Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis publication-title: Eur J Cancer – volume: 126 start-page: 33 year: 2020 end-page: 44 ident: bib144 article-title: Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma publication-title: Eur J Cancer – volume: 8 year: 2020 ident: bib182 article-title: Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG∗ study in 380 patients publication-title: Journal for immunotherapy of cancer – volume: 31 start-page: 482 year: 2021 end-page: 486 ident: bib192 article-title: Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis publication-title: Melanoma Res – volume: 47 start-page: 1476 year: 2011 end-page: 1483 ident: bib164 article-title: Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032) publication-title: Eur J Cancer – volume: 19 start-page: 1195 year: 2008 end-page: 1201 ident: bib83 article-title: Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis publication-title: Ann Oncol – volume: 10 start-page: 602705 year: 2020 ident: bib193 article-title: Immune checkpoint inhibitors in advanced acral melanoma: a systematic review publication-title: Front Oncol – volume: 39 start-page: 9508 year: 2021 ident: bib178 article-title: Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): randomized phase 2 study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets) publication-title: J Clin Oncol – volume: 16 start-page: 1049 year: 2015 end-page: 1060 ident: bib58 article-title: Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial publication-title: Lancet Oncol – volume: 26 start-page: 218 year: 2003 end-page: 222 ident: bib3 article-title: Surgical standards in the primary care of melanoma patients publication-title: Onkologie – start-page: 1 year: 2021 end-page: 8 ident: bib70 article-title: Immunotherapy and radiotherapy in melanoma: a multidisciplinary comprehensive review publication-title: Hum Vaccines Immunother – volume: 6 start-page: 285 year: 1989 end-page: 289 ident: bib167 article-title: Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: a randomized phase II study publication-title: Med Oncol Tumor Pharmacother – volume: 39 start-page: 9504 year: 2021 ident: bib190 article-title: Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: updated findings of LEAP-004 publication-title: J Clin Oncol – volume: 13 start-page: 459 year: 2012 end-page: 465 ident: bib175 article-title: Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial publication-title: Lancet Oncol – volume: 16 start-page: 1425 year: 1998 end-page: 1429 ident: bib82 article-title: Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group publication-title: J Clin Oncol – volume: 366 start-page: 707 year: 2012 end-page: 714 ident: bib116 article-title: Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib publication-title: N Engl J Med – volume: 38 start-page: 10019 year: 2020 ident: bib198 article-title: CheckMate 067: long-term outcomes in patients with mucosal melanoma publication-title: J Clin Oncol – volume: 144 start-page: 943 year: 2008 end-page: 945 ident: bib26 article-title: Imiquimod treatment of lentigo maligna: an open-label study of 34 primary lesions in 32 patients publication-title: Arch Dermatol – volume: 214 start-page: 491 year: 1991 end-page: 499 ident: bib46 article-title: Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic publication-title: Ann Surg – volume: 39 start-page: 9506 year: 2021 ident: bib132 article-title: CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma publication-title: J Clin Oncol – volume: 373 start-page: 1270 year: 2015 end-page: 1271 ident: bib139 article-title: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma publication-title: N Engl J Med – volume: 358 start-page: 866 year: 2001 end-page: 869 ident: bib86 article-title: Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial publication-title: Lancet (London, England) – volume: 39 start-page: 9507 year: 2021 ident: bib146 article-title: Five-year overall survival (OS) in COLUMBUS: a randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma publication-title: J Clin Oncol – volume: 94 start-page: 287 year: 2006 end-page: 292 ident: bib32 article-title: Mohs micrographic surgery in the treatment of lentigo maligna and melanoma publication-title: J Surg Oncol – volume: 51 start-page: 2404 year: 2015 end-page: 2412 ident: bib199 article-title: Uveal melanoma UK national guidelines publication-title: Eur J Cancer – volume: 39 start-page: 356154 year: 2021 ident: bib157 article-title: DREAMseq (doublet, randomized evaluation in advanced melanoma sequencing): a phase III trial—ECOG-ACRIN EA6134 publication-title: J Clin Oncol – volume: 146 start-page: 1042 year: 2002 end-page: 1046 ident: bib56 article-title: A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays publication-title: Br J Dermatol – start-page: JCO1801219 year: 2018 ident: bib106 article-title: Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage III melanoma publication-title: J Clin Oncol – volume: 17 start-page: 325 year: 2007 end-page: 331 ident: bib2 article-title: Management of adult patients with cutaneous melanoma without distant metastasis. 2005 update of the French Standards, Options and Recommendations guidelines. Summary report publication-title: Eur J Dermatol : EJD. – volume: 27 start-page: 301 year: 2021 end-page: 309 ident: bib107 article-title: Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC) publication-title: Nat Med – volume: 15 start-page: 954 year: 2014 end-page: 965 ident: bib152 article-title: Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study publication-title: Lancet Oncol – volume: 9 start-page: 491 year: 1999 end-page: 502 ident: bib48 article-title: Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study publication-title: Melanoma Res – volume: 363 start-page: 711 year: 2010 end-page: 723 ident: bib111 article-title: Improved survival with ipilimumab in patients with metastatic melanoma publication-title: N Engl J Med – volume: 22 start-page: 787 year: 2011 end-page: 793 ident: bib163 article-title: Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma publication-title: Ann Oncol – volume: 23 start-page: 1493 year: 1999 end-page: 1498 ident: bib31 article-title: Patterns of local horizontal spread of melanomas: consequences for surgery and histopathologic investigation publication-title: Am J Surg Pathol – volume: 242 start-page: 302 year: 2005 end-page: 311 ident: bib36 article-title: Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial publication-title: Ann Surg – volume: 39 start-page: 9503 year: 2021 ident: bib160 article-title: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: primary phase III results from RELATIVITY-047 (CA224-047) publication-title: J Clin Oncol – volume: 20 start-page: 1239 year: 2019 end-page: 1251 ident: bib186 article-title: Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study publication-title: Lancet Oncol – volume: 130 start-page: 104 year: 2019 end-page: 112 ident: bib68 article-title: Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: an international meta-analysis of individual patient data publication-title: Radiother Oncol – volume: 47 start-page: 1558 year: 2021 end-page: 1574 ident: bib15 article-title: Surgical excision margins in primary cutaneous melanoma: a systematic review and meta-analysis publication-title: Eur J Surg Oncol – volume: 7 start-page: 145 year: 2019 ident: bib159 article-title: Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma publication-title: Journal for immunotherapy of cancer – volume: 351 start-page: 1905 year: 1998 end-page: 1910 ident: bib89 article-title: Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma publication-title: Lancet (London, England) – volume: 31 start-page: S672 year: 2020 end-page: S710 ident: bib204 article-title: 1080MO - the value of local therapy in treatment of solitary melanoma progression upon immune checkpoint inhibition publication-title: Ann Oncol – volume: 185 start-page: 675 year: 2021 end-page: 677 ident: bib25 article-title: Real-world experience of off-label use of imiquimod 5% as an adjuvant therapy after surgery or as a monotherapy for lentigo maligna publication-title: Br J Dermatol – volume: 364 start-page: 2507 year: 2011 end-page: 2516 ident: bib110 article-title: Improved survival with vemurafenib in melanoma with BRAF V600E mutation publication-title: N Engl J Med – volume: 27 start-page: 559 year: 2016 end-page: 574 ident: bib121 article-title: Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper publication-title: Ann Oncol – volume: 29 start-page: viii737 year: 2018 ident: bib134 article-title: Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511) publication-title: Ann Oncol – volume: 15 start-page: 859 year: 1988 end-page: 864 ident: bib60 article-title: Palliative radiotherapy for metastatic malignant melanoma: brain metastases, bone metastases, and spinal cord compression publication-title: Int J Radiat Oncol Biol Phys – volume: 25 start-page: 54 year: 2015 end-page: 64 ident: bib67 article-title: Current clinical trials testing combinations of immunotherapy and radiation publication-title: Semin Radiat Oncol – volume: 13 start-page: 2776 year: 1995 end-page: 2783 ident: bib93 article-title: Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma publication-title: J Clin Oncol – volume: 62 start-page: 1061 year: 1988 end-page: 1065 ident: bib174 article-title: Combination of cisplatin, vindesine, and dacarbazine in advanced malignant melanoma. A phase II study of the EORTC malignant melanoma cooperative group publication-title: Cancer – volume: 355 start-page: 1307 year: 2006 end-page: 1317 ident: bib40 article-title: Sentinel-node biopsy or nodal observation in melanoma publication-title: N Engl J Med – year: 2018 ident: bib16 article-title: Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik, Therapie und Nachsorge des Melanoms, Langversion 3.1 – volume: 377 start-page: 1824 year: 2017 end-page: 1835 ident: bib76 article-title: Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma publication-title: N Engl J Med – volume: 376 start-page: 2211 year: 2017 end-page: 2222 ident: bib37 article-title: Completion dissection or observation for sentinel-node metastasis in melanoma publication-title: N Engl J Med – volume: 29 start-page: 806 year: 2021 end-page: 815 ident: bib45 article-title: Adjuvant therapy for stage III melanoma without immediate completion lymph node dissection publication-title: Ann Surg Oncol – volume: 375 start-page: 1845 year: 2016 end-page: 1855 ident: bib78 article-title: Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy publication-title: N Engl J Med – volume: 38 start-page: 10000 year: 2020 ident: bib99 article-title: Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: new recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up publication-title: J Clin Oncol – volume: 13 start-page: 910 year: 1995 end-page: 913 ident: bib170 article-title: Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma publication-title: J Clin Oncol – volume: 38 start-page: 10019 year: 2020 ident: 10.1016/j.ejca.2022.04.018_bib198 article-title: CheckMate 067: long-term outcomes in patients with mucosal melanoma publication-title: J Clin Oncol doi: 10.1200/JCO.2020.38.15_suppl.10019 – volume: 31 start-page: 616 year: 2017 ident: 10.1016/j.ejca.2022.04.018_bib23 article-title: A systematic review on the role of imiquimod in lentigo maligna and lentigo maligna melanoma: need for standardization of treatment schedule and outcome measures publication-title: J Eur Acad Dermatol Venereol : JEADV doi: 10.1111/jdv.14085 – year: 2019 ident: 10.1016/j.ejca.2022.04.018_bib43 article-title: Final analysis of DeCOG-SLT trial: No survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node publication-title: J Clin Oncol doi: 10.1200/JCO.18.02306 – volume: 126 start-page: 33 year: 2020 ident: 10.1016/j.ejca.2022.04.018_bib144 article-title: Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma publication-title: Eur J Cancer doi: 10.1016/j.ejca.2019.11.016 – volume: 32 start-page: S1283 issue: suppl_5 year: 2021 ident: 10.1016/j.ejca.2022.04.018_bib156 article-title: LBA40 - SECOMBIT: the best sequential approach with combo immunotherapy ipilimumab (I)/nivolumab (N) and combo target therapy encorafenib (E)/binimetinib (B) in patients with BRAF mutated metastatic melanoma: a phase II randomized study publication-title: Ann Oncol – volume: 36 start-page: 399 year: 2018 ident: 10.1016/j.ejca.2022.04.018_bib38 article-title: Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American society of clinical oncology and society of surgical oncology clinical practice guideline update publication-title: J Clin Oncol doi: 10.1200/JCO.2017.75.7724 – volume: 61 start-page: 243 year: 1988 ident: 10.1016/j.ejca.2022.04.018_bib62 article-title: Analysis of dose fractionation in the palliation of metastases from malignant melanoma publication-title: Cancer doi: 10.1002/1097-0142(19880115)61:2<243::AID-CNCR2820610207>3.0.CO;2-K – volume: 32 start-page: S1283 issue: suppl_5 year: 2021 ident: 10.1016/j.ejca.2022.04.018_bib79 article-title: LBA3 PR - pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: efficacy and safety results from the KEYNOTE-716 double-blind phase III trial publication-title: Ann Oncol – volume: 12 start-page: 5155 year: 2021 ident: 10.1016/j.ejca.2022.04.018_bib202 article-title: The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma publication-title: Nat Commun doi: 10.1038/s41467-021-25332-w – volume: 378 start-page: 1635 year: 2011 ident: 10.1016/j.ejca.2022.04.018_bib14 article-title: 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial publication-title: Lancet (London, England) doi: 10.1016/S0140-6736(11)61546-8 – volume: 27 start-page: 5121 year: 2020 ident: 10.1016/j.ejca.2022.04.018_bib44 article-title: Adjuvant therapy is effective for melanoma patients with a positive sentinel lymph node biopsy who Forego completion lymphadenectomy publication-title: Ann Surg Oncol doi: 10.1245/s10434-020-08478-7 – volume: 20 start-page: 948 year: 2019 ident: 10.1016/j.ejca.2022.04.018_bib108 article-title: Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(19)30151-2 – volume: 372 start-page: 2521 year: 2015 ident: 10.1016/j.ejca.2022.04.018_bib138 article-title: Pembrolizumab versus ipilimumab in advanced melanoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1503093 – volume: 366 start-page: 707 year: 2012 ident: 10.1016/j.ejca.2022.04.018_bib116 article-title: Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib publication-title: N Engl J Med doi: 10.1056/NEJMoa1112302 – volume: 379 start-page: 1893 year: 2012 ident: 10.1016/j.ejca.2022.04.018_bib118 article-title: Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial publication-title: Lancet doi: 10.1016/S0140-6736(12)60398-5 – start-page: JCO1801219 year: 2018 ident: 10.1016/j.ejca.2022.04.018_bib106 article-title: Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage III melanoma publication-title: J Clin Oncol – volume: 110 start-page: 1791 year: 2007 ident: 10.1016/j.ejca.2022.04.018_bib59 article-title: A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma publication-title: Cancer doi: 10.1002/cncr.22988 – volume: 25 start-page: 2086 year: 2014 ident: 10.1016/j.ejca.2022.04.018_bib180 article-title: On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases publication-title: Ann Oncol doi: 10.1093/annonc/mdu266 – volume: 119 start-page: 1 year: 2019 ident: 10.1016/j.ejca.2022.04.018_bib96 article-title: Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial publication-title: Eur J Cancer doi: 10.1016/j.ejca.2019.07.001 – volume: 107 start-page: 422 year: 2012 ident: 10.1016/j.ejca.2022.04.018_bib50 article-title: Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis publication-title: British journal of cancer doi: 10.1038/bjc.2012.306 – volume: 37 start-page: 867 year: 2019 ident: 10.1016/j.ejca.2022.04.018_bib133 article-title: Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb/IV CheckMate 511 trial publication-title: J Clin Oncol doi: 10.1200/JCO.18.01998 – volume: 366 start-page: 2443 year: 2012 ident: 10.1016/j.ejca.2022.04.018_bib137 article-title: Safety, activity, and immune correlates of anti–PD-1 antibody in cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1200690 – volume: 13 start-page: 910 year: 1995 ident: 10.1016/j.ejca.2022.04.018_bib170 article-title: Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma publication-title: J Clin Oncol doi: 10.1200/JCO.1995.13.4.910 – volume: 358 start-page: 866 year: 2001 ident: 10.1016/j.ejca.2022.04.018_bib86 article-title: Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial publication-title: Lancet (London, England) doi: 10.1016/S0140-6736(01)06068-8 – volume: 18 start-page: 435 year: 2017 ident: 10.1016/j.ejca.2022.04.018_bib148 article-title: Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(17)30180-8 – volume: 174 start-page: 588 year: 2016 ident: 10.1016/j.ejca.2022.04.018_bib20 article-title: Recurrence rate of lentigo maligna after micrographically controlled staged surgical excision publication-title: Br J Dermatol doi: 10.1111/bjd.14325 – volume: 364 start-page: 2507 year: 2011 ident: 10.1016/j.ejca.2022.04.018_bib110 article-title: Improved survival with vemurafenib in melanoma with BRAF V600E mutation publication-title: N Engl J Med doi: 10.1056/NEJMoa1103782 – start-page: 8508 year: 2007 ident: 10.1016/j.ejca.2022.04.018_bib114 article-title: An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites publication-title: J clinic oncol doi: 10.1200/jco.2007.25.18_suppl.8508 – volume: 29 start-page: viii737 year: 2018 ident: 10.1016/j.ejca.2022.04.018_bib134 article-title: Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511) publication-title: Ann Oncol doi: 10.1093/annonc/mdy424.057 – volume: 94 start-page: 287 year: 2006 ident: 10.1016/j.ejca.2022.04.018_bib32 article-title: Mohs micrographic surgery in the treatment of lentigo maligna and melanoma publication-title: J Surg Oncol doi: 10.1002/jso.20305 – volume: 37 year: 2019 ident: 10.1016/j.ejca.2022.04.018_bib184 article-title: A phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab plus nivolumab alone in patients with melanoma brain metastases (ABC-X Trial) publication-title: J Clin Oncol doi: 10.1200/JCO.2019.37.15_suppl.TPS9600 – volume: 11 start-page: 354 year: 2021 ident: 10.1016/j.ejca.2022.04.018_bib72 article-title: Radiation therapy for brain metastases: a systematic review publication-title: Practical radiation oncology doi: 10.1016/j.prro.2021.04.002 – volume: 29 start-page: 806 year: 2021 ident: 10.1016/j.ejca.2022.04.018_bib45 article-title: Adjuvant therapy for stage III melanoma without immediate completion lymph node dissection publication-title: Ann Surg Oncol doi: 10.1245/s10434-021-10775-8 – volume: 20 start-page: 1239 year: 2019 ident: 10.1016/j.ejca.2022.04.018_bib186 article-title: Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(19)30388-2 – volume: 377 start-page: 1824 year: 2017 ident: 10.1016/j.ejca.2022.04.018_bib76 article-title: Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1709030 – volume: 19 start-page: 1480 year: 2018 ident: 10.1016/j.ejca.2022.04.018_bib125 article-title: Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(18)30700-9 – volume: 163 start-page: 238 year: 2010 ident: 10.1016/j.ejca.2022.04.018_bib10 article-title: Revised U.K. guidelines for the management of cutaneous melanoma 2010 publication-title: Br J Dermatol doi: 10.1111/j.1365-2133.2010.09883.x – volume: 5 start-page: 43 year: 2017 ident: 10.1016/j.ejca.2022.04.018_bib129 article-title: Evaluation of dosing strategy for pembrolizumab for oncology indications publication-title: Journal for immunotherapy of cancer doi: 10.1186/s40425-017-0242-5 – volume: 27 start-page: 5280 year: 2021 ident: 10.1016/j.ejca.2022.04.018_bib81 article-title: Standard-dose pembrolizumab plus alternate-dose ipilimumab in advanced melanoma: KEYNOTE-029 cohort 1C, a phase 2 randomized study of two dosing schedules publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-21-0793 – volume: 13 start-page: 458 year: 2001 ident: 10.1016/j.ejca.2022.04.018_bib169 article-title: Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma publication-title: Clin Oncol – volume: 13 start-page: 459 year: 2012 ident: 10.1016/j.ejca.2022.04.018_bib175 article-title: Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(12)70090-6 – volume: 31 start-page: S1142 issue: suppl_4 year: 2020 ident: 10.1016/j.ejca.2022.04.018_bib100 article-title: LBA46 - pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: final results regarding distant metastasis-free survival from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial publication-title: Ann Oncol – volume: 29 start-page: 366 year: 2003 ident: 10.1016/j.ejca.2022.04.018_bib30 article-title: “Functional” surgery in subungual melanoma publication-title: Dermatol Surg – volume: 25 start-page: iv392 issue: suppl 4 year: 2014 ident: 10.1016/j.ejca.2022.04.018_bib154 article-title: 1130TiP- NEMO: a phase 3 trial OF binimetinib (MEK162) versus dacarbazine IN patients with advanced NRAS-mutant melanoma who are untreated or have progressed after any number of immunotherapy regimens publication-title: Ann Oncol doi: 10.1093/annonc/mdu344.46 – volume: 27 start-page: 559 year: 2016 ident: 10.1016/j.ejca.2022.04.018_bib121 article-title: Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper publication-title: Ann Oncol doi: 10.1093/annonc/mdv623 – volume: 366 start-page: 1189 year: 2005 ident: 10.1016/j.ejca.2022.04.018_bib91 article-title: Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial publication-title: Lancet (London, England) doi: 10.1016/S0140-6736(05)67482-X – volume: 5 start-page: 243 year: 2019 ident: 10.1016/j.ejca.2022.04.018_bib181 article-title: Comparison of local control of brain metastases with stereotactic radiosurgery vs surgical resection: a secondary analysis of a randomized clinical trial publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2018.4610 – volume: 364 start-page: 2517 year: 2011 ident: 10.1016/j.ejca.2022.04.018_bib120 article-title: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1104621 – volume: 42 start-page: 186 year: 2019 ident: 10.1016/j.ejca.2022.04.018_bib183 article-title: Combination of immunotherapy and brain radiotherapy in metastatic melanoma: a retrospective analysis publication-title: Oncology research and treatment doi: 10.1159/000497211 – volume: 12 start-page: 1027 year: 2020 ident: 10.1016/j.ejca.2022.04.018_bib113 article-title: Primary resistance to PD-1-based immunotherapy-A study in 319 patients with stage IV melanoma publication-title: Cancers doi: 10.3390/cancers12041027 – volume: 146 start-page: 1042 year: 2002 ident: 10.1016/j.ejca.2022.04.018_bib56 article-title: A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays publication-title: Br J Dermatol doi: 10.1046/j.1365-2133.2002.04750.x – volume: 19 start-page: 510 year: 2018 ident: 10.1016/j.ejca.2022.04.018_bib103 article-title: Adjuvant vemurafenib in resected, BRAF(V600) mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(18)30106-2 – volume: 61 start-page: 419 year: 2008 ident: 10.1016/j.ejca.2022.04.018_bib27 article-title: Topical imiquimod therapy for lentigo maligna publication-title: Ann Plast Surg doi: 10.1097/SAP.0b013e31816714c8 – volume: 30 start-page: 582 year: 2019 ident: 10.1016/j.ejca.2022.04.018_bib126 article-title: Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 publication-title: Ann Oncol doi: 10.1093/annonc/mdz011 – volume: 26 start-page: 218 year: 2003 ident: 10.1016/j.ejca.2022.04.018_bib3 article-title: Surgical standards in the primary care of melanoma patients publication-title: Onkologie – volume: 22 start-page: 787 year: 2011 ident: 10.1016/j.ejca.2022.04.018_bib163 article-title: Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma publication-title: Ann Oncol doi: 10.1093/annonc/mdq438 – volume: 84 start-page: 1146 year: 2001 ident: 10.1016/j.ejca.2022.04.018_bib87 article-title: Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study publication-title: British journal of cancer doi: 10.1054/bjoc.2000.1623 – volume: 154 start-page: 453 year: 2006 ident: 10.1016/j.ejca.2022.04.018_bib18 article-title: Conventional histology vs. three-dimensional histology in lentigo maligna melanoma publication-title: Br J Dermatol doi: 10.1111/j.1365-2133.2005.07068.x – volume: 130 start-page: 104 year: 2019 ident: 10.1016/j.ejca.2022.04.018_bib68 article-title: Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: an international meta-analysis of individual patient data publication-title: Radiother Oncol doi: 10.1016/j.radonc.2018.08.025 – volume: 47 start-page: 1476 year: 2011 ident: 10.1016/j.ejca.2022.04.018_bib164 article-title: Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032) publication-title: Eur J Cancer doi: 10.1016/j.ejca.2011.04.030 – volume: 7 start-page: 299 year: 2019 ident: 10.1016/j.ejca.2022.04.018_bib200 article-title: Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study publication-title: Journal for immunotherapy of cancer doi: 10.1186/s40425-019-0800-0 – volume: 28 start-page: iv119 year: 2017 ident: 10.1016/j.ejca.2022.04.018_bib122 article-title: Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up publication-title: Ann Oncol doi: 10.1093/annonc/mdx225 – volume: 27 start-page: 301 year: 2021 ident: 10.1016/j.ejca.2022.04.018_bib107 article-title: Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC) publication-title: Nat Med doi: 10.1038/s41591-020-01188-3 – volume: 33 start-page: 2780 year: 2015 ident: 10.1016/j.ejca.2022.04.018_bib47 article-title: Talimogene laherparepvec improves durable response rate in patients with advanced melanoma publication-title: J Clin Oncol doi: 10.1200/JCO.2014.58.3377 – volume: 81 start-page: CT008 year: 2021 ident: 10.1016/j.ejca.2022.04.018_bib189 article-title: Abstract CT008: lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced (unresectable or metastatic) melanoma: durable duration of response at 28 month follow up publication-title: Cancer Res doi: 10.1158/1538-7445.AM2021-CT008 – volume: 377 start-page: 1345 year: 2017 ident: 10.1016/j.ejca.2022.04.018_bib136 article-title: Overall survival with combined nivolumab and ipilimumab in advanced melanoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1709684 – volume: 40 start-page: 390 year: 2004 ident: 10.1016/j.ejca.2022.04.018_bib84 article-title: Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis publication-title: Eur J Cancer doi: 10.1016/j.ejca.2003.07.004 – volume: 372 start-page: 30 year: 2015 ident: 10.1016/j.ejca.2022.04.018_bib149 article-title: Improved overall survival in melanoma with combined dabrafenib and trametinib publication-title: N Engl J Med doi: 10.1056/NEJMoa1412690 – volume: 355 start-page: 1307 year: 2006 ident: 10.1016/j.ejca.2022.04.018_bib40 article-title: Sentinel-node biopsy or nodal observation in melanoma publication-title: N Engl J Med doi: 10.1056/NEJMoa060992 – volume: 39 start-page: 9525 year: 2021 ident: 10.1016/j.ejca.2022.04.018_bib105 article-title: Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event (AE) management algorithm in patients (pts) treated with adjuvant dabrafenib + trametinib (dab + tram): primary results of COMBI-APlus publication-title: J Clin Oncol doi: 10.1200/JCO.2021.39.15_suppl.9525 – volume: 36 start-page: 3062 year: 2018 ident: 10.1016/j.ejca.2022.04.018_bib128 article-title: A six-weekly (Q6W) dosing schedule for pembrolizumab based on an exposure-response (E-R) evaluation using modeling and simulation publication-title: J Clin Oncol doi: 10.1200/JCO.2018.36.15_suppl.3062 – volume: 25 start-page: 263 year: 1990 ident: 10.1016/j.ejca.2022.04.018_bib171 article-title: Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma publication-title: Cancer Chemother Pharmacol doi: 10.1007/BF00684883 – volume: 7 start-page: 250 year: 2009 ident: 10.1016/j.ejca.2022.04.018_bib7 article-title: Melanoma publication-title: J Natl Compr Cancer Netw : JNCCN. doi: 10.6004/jnccn.2009.0020 – volume: 10 start-page: 602705 year: 2020 ident: 10.1016/j.ejca.2022.04.018_bib193 article-title: Immune checkpoint inhibitors in advanced acral melanoma: a systematic review publication-title: Front Oncol doi: 10.3389/fonc.2020.602705 – volume: 133 start-page: 104 year: 2007 ident: 10.1016/j.ejca.2022.04.018_bib51 article-title: Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma publication-title: J Thorac Cardiovasc Surg doi: 10.1016/j.jtcvs.2006.08.065 – volume: 19 start-page: 603 year: 2018 ident: 10.1016/j.ejca.2022.04.018_bib143 article-title: Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(18)30142-6 – volume: 32 start-page: S867 issue: suppl_5 year: 2021 ident: 10.1016/j.ejca.2022.04.018_bib158 article-title: 1037O - MASTERKEY-265: a phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL) publication-title: Ann Oncol – volume: 28 start-page: 6168 year: 2021 ident: 10.1016/j.ejca.2022.04.018_bib6 article-title: Impact of shave biopsy on diagnosis and management of cutaneous melanoma: a systematic review and meta-analysis publication-title: Ann Surg Oncol doi: 10.1245/s10434-021-09866-3 – volume: 12 start-page: 144 year: 2011 ident: 10.1016/j.ejca.2022.04.018_bib90 article-title: Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(10)70288-6 – volume: 223 start-page: 241 year: 2011 ident: 10.1016/j.ejca.2022.04.018_bib115 article-title: A new era: melanoma genetics and therapeutics publication-title: J Pathol doi: 10.1002/path.2804 – volume: 242 start-page: 302 year: 2005 ident: 10.1016/j.ejca.2022.04.018_bib36 article-title: Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial publication-title: Ann Surg doi: 10.1097/01.sla.0000181092.50141.fa – volume: 18 start-page: 158 year: 2000 ident: 10.1016/j.ejca.2022.04.018_bib166 article-title: Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma publication-title: J Clin Oncol doi: 10.1200/JCO.2000.18.1.158 – volume: 21 start-page: 1465 year: 2020 ident: 10.1016/j.ejca.2022.04.018_bib97 article-title: Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(20)30494-0 – volume: 19 start-page: 1195 year: 2008 ident: 10.1016/j.ejca.2022.04.018_bib83 article-title: Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis publication-title: Ann Oncol doi: 10.1093/annonc/mdn001 – volume: 10 year: 2021 ident: 10.1016/j.ejca.2022.04.018_bib195 article-title: Molecular markers and targets in melanoma publication-title: Cells doi: 10.3390/cells10092320 – volume: 103 start-page: 614 year: 2012 ident: 10.1016/j.ejca.2022.04.018_bib21 article-title: Conventional surgery compared with slow Mohs micrographic surgery in the treatment of lentigo maligna: a retrospective study of 62 cases publication-title: Actas Dermo-Sifiliográficas doi: 10.1016/j.ad.2011.12.009 – volume: 372 start-page: 117 year: 2008 ident: 10.1016/j.ejca.2022.04.018_bib94 article-title: Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial publication-title: Lancet (London, England) doi: 10.1016/S0140-6736(08)61033-8 – volume: 162 start-page: 22 year: 2021 ident: 10.1016/j.ejca.2022.04.018_bib162 article-title: Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis publication-title: Eur J Cancer doi: 10.1016/j.ejca.2021.11.022 – volume: 38 start-page: 10000 year: 2020 ident: 10.1016/j.ejca.2022.04.018_bib99 article-title: Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: new recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up publication-title: J Clin Oncol doi: 10.1200/JCO.2020.38.15_suppl.10000 – volume: 47 start-page: 1558 year: 2021 ident: 10.1016/j.ejca.2022.04.018_bib15 article-title: Surgical excision margins in primary cutaneous melanoma: a systematic review and meta-analysis publication-title: Eur J Surg Oncol doi: 10.1016/j.ejso.2021.02.025 – volume: 372 start-page: 320 year: 2014 ident: 10.1016/j.ejca.2022.04.018_bib124 article-title: Nivolumab in previously untreated melanoma without BRAF mutation publication-title: N Engl J Med doi: 10.1056/NEJMoa1412082 – volume: 35 start-page: 313 year: 2009 ident: 10.1016/j.ejca.2022.04.018_bib52 article-title: Surgery for melanoma metastases of the gastrointestinal tract: indications and results publication-title: Eur J Surg Oncol doi: 10.1016/j.ejso.2008.04.011 – volume: 39 start-page: 9502 year: 2021 ident: 10.1016/j.ejca.2022.04.018_bib109 article-title: Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma publication-title: J Clin Oncol doi: 10.1200/JCO.2021.39.15_suppl.9502 – volume: 16 start-page: 1425 year: 1998 ident: 10.1016/j.ejca.2022.04.018_bib82 article-title: Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group publication-title: J Clin Oncol doi: 10.1200/JCO.1998.16.4.1425 – volume: 18 start-page: 863 year: 2017 ident: 10.1016/j.ejca.2022.04.018_bib179 article-title: Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(17)30429-1 – volume: 31 start-page: 482 year: 2021 ident: 10.1016/j.ejca.2022.04.018_bib192 article-title: Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis publication-title: Melanoma Res doi: 10.1097/CMR.0000000000000764 – volume: 376 start-page: 2211 year: 2017 ident: 10.1016/j.ejca.2022.04.018_bib37 article-title: Completion dissection or observation for sentinel-node metastasis in melanoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1613210 – volume: 351 start-page: 1905 year: 1998 ident: 10.1016/j.ejca.2022.04.018_bib89 article-title: Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma publication-title: Lancet (London, England) doi: 10.1016/S0140-6736(97)12445-X – volume: 3 year: 2014 ident: 10.1016/j.ejca.2022.04.018_bib66 article-title: Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy publication-title: OncoImmunology doi: 10.4161/onci.28780 – volume: 36 start-page: 9504 year: 2018 ident: 10.1016/j.ejca.2022.04.018_bib153 article-title: Overall survival in COLUMBUS: a phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma publication-title: J Clin Oncol doi: 10.1200/JCO.2018.36.15_suppl.9504 – volume: 8 year: 2020 ident: 10.1016/j.ejca.2022.04.018_bib182 article-title: Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG∗ study in 380 patients publication-title: Journal for immunotherapy of cancer doi: 10.1136/jitc-2019-000333 – volume: 395 start-page: 1558 year: 2020 ident: 10.1016/j.ejca.2022.04.018_bib80 article-title: Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial publication-title: Lancet (London, England) doi: 10.1016/S0140-6736(20)30417-7 – volume: 18 start-page: 152 year: 2008 ident: 10.1016/j.ejca.2022.04.018_bib11 article-title: Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting publication-title: Melanoma Res doi: 10.1097/CMR.0b013e3282f702bf – volume: 33 start-page: 1889 year: 2015 ident: 10.1016/j.ejca.2022.04.018_bib123 article-title: Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma publication-title: J Clin Oncol doi: 10.1200/JCO.2014.56.2736 – volume: 12 year: 2017 ident: 10.1016/j.ejca.2022.04.018_bib194 article-title: Variables that influence BRAF mutation probability: a next-generation sequencing, non-interventional investigation of BRAFV600 mutation status in melanoma publication-title: PLoS One doi: 10.1371/journal.pone.0188602 – volume: 27 start-page: 6199 year: 2009 ident: 10.1016/j.ejca.2022.04.018_bib95 article-title: Final version of 2009 AJCC melanoma staging and classification publication-title: J Clin Oncol doi: 10.1200/JCO.2009.23.4799 – volume: 32 start-page: 9011 year: 2014 ident: 10.1016/j.ejca.2022.04.018_bib150 publication-title: J Clin Oncol doi: 10.1200/jco.2014.32.15_suppl.9011 – volume: 47 start-page: 1539 year: 2021 ident: 10.1016/j.ejca.2022.04.018_bib22 article-title: Systematic review of technical variations for Mohs micrographic surgery for melanoma publication-title: Dermatol Surg doi: 10.1097/DSS.0000000000003268 – volume: 11 start-page: 1 issue: Suppl 6 year: 2013 ident: 10.1016/j.ejca.2022.04.018_bib17 article-title: Malignant melanoma S3-guideline “diagnosis, therapy and follow-up of melanoma” publication-title: J Dtsch Dermatol Ges – volume: 24 start-page: 3164 year: 2006 ident: 10.1016/j.ejca.2022.04.018_bib55 article-title: Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses publication-title: J Clin Oncol doi: 10.1200/JCO.2005.05.2498 – volume: 11 start-page: 189 year: 2001 ident: 10.1016/j.ejca.2022.04.018_bib168 article-title: Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients publication-title: Melanoma Res doi: 10.1097/00008390-200104000-00015 – volume: 38 start-page: 10001 year: 2020 ident: 10.1016/j.ejca.2022.04.018_bib104 article-title: Long-term benefit of adjuvant dabrafenib + trametinib (D+T) in patients (pts) with resected stage III BRAF V600–mutant melanoma: Five-year analysis of COMBI-AD publication-title: J Clin Oncol doi: 10.1200/JCO.2020.38.15_suppl.10001 – year: 2021 ident: 10.1016/j.ejca.2022.04.018_bib145 article-title: 5-Year outcomes with cobimetinib plus vemurafenib in BRAF (V600) mutation-positive advanced melanoma: extended follow-up of the coBRIM study publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-21-0809 – year: 2021 ident: 10.1016/j.ejca.2022.04.018_bib102 article-title: Adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in patients with resected stage IIIB-D/IV melanoma (CheckMate 915) – volume: 16 start-page: 522 year: 2015 ident: 10.1016/j.ejca.2022.04.018_bib75 article-title: Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)70122-1 – start-page: 1 year: 2021 ident: 10.1016/j.ejca.2022.04.018_bib70 article-title: Immunotherapy and radiotherapy in melanoma: a multidisciplinary comprehensive review publication-title: Hum Vaccines Immunother – volume: 19 start-page: 627 year: 2012 ident: 10.1016/j.ejca.2022.04.018_bib49 article-title: 20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose matters publication-title: Ann Surg Oncol doi: 10.1245/s10434-011-2030-7 – volume: 25 start-page: 54 year: 2015 ident: 10.1016/j.ejca.2022.04.018_bib67 article-title: Current clinical trials testing combinations of immunotherapy and radiation publication-title: Semin Radiat Oncol doi: 10.1016/j.semradonc.2014.07.003 – volume: 13 start-page: 589 year: 2012 ident: 10.1016/j.ejca.2022.04.018_bib57 article-title: Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(12)70138-9 – volume: 16 start-page: 35 year: 2007 ident: 10.1016/j.ejca.2022.04.018_bib35 article-title: Sentinel node mapping for melanoma: results of trials and current applications publication-title: Surg Oncol Clin doi: 10.1016/j.soc.2006.10.013 – volume: 72 start-page: 1047 year: 2015 ident: 10.1016/j.ejca.2022.04.018_bib24 article-title: Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type publication-title: J Am Acad Dermatol doi: 10.1016/j.jaad.2015.02.008 – volume: 363 start-page: 711 year: 2010 ident: 10.1016/j.ejca.2022.04.018_bib111 article-title: Improved survival with ipilimumab in patients with metastatic melanoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1003466 – volume: 7 start-page: 145 year: 2019 ident: 10.1016/j.ejca.2022.04.018_bib159 article-title: Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma publication-title: Journal for immunotherapy of cancer doi: 10.1186/s40425-019-0623-z – volume: 379 start-page: 722 year: 2018 ident: 10.1016/j.ejca.2022.04.018_bib176 article-title: Combined nivolumab and ipilimumab in melanoma metastatic to the brain publication-title: N Engl J Med doi: 10.1056/NEJMoa1805453 – volume: 348 start-page: 62 year: 2015 ident: 10.1016/j.ejca.2022.04.018_bib188 article-title: Adoptive cell transfer as personalized immunotherapy for human cancer publication-title: Science (New York, NY) doi: 10.1126/science.aaa4967 – volume: 378 start-page: 1789 year: 2018 ident: 10.1016/j.ejca.2022.04.018_bib98 article-title: Adjuvant pembrolizumab versus placebo in resected stage III melanoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1802357 – volume: 39 start-page: 9500 year: 2021 ident: 10.1016/j.ejca.2022.04.018_bib101 article-title: Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma publication-title: J Clin Oncol doi: 10.1200/JCO.2021.39.15_suppl.9500 – volume: 135 start-page: 22 year: 2020 ident: 10.1016/j.ejca.2022.04.018_bib197 article-title: Ano-uro-genital mucosal melanoma UK national guidelines publication-title: Eur J Cancer doi: 10.1016/j.ejca.2020.04.030 – volume: 7 start-page: 907 year: 1981 ident: 10.1016/j.ejca.2022.04.018_bib61 article-title: The results of different fractionation schemes in the palliative irradiation of metastatic melanoma publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/0360-3016(81)90007-9 – year: 2008 ident: 10.1016/j.ejca.2022.04.018_bib8 article-title: Australian cancer network melanoma guidelines revision working party – volume: 11 start-page: 909 year: 2012 ident: 10.1016/j.ejca.2022.04.018_bib117 article-title: Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations publication-title: Mol Cancer Therapeut doi: 10.1158/1535-7163.MCT-11-0989 – volume: 13 start-page: 97 year: 2003 ident: 10.1016/j.ejca.2022.04.018_bib172 article-title: A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma publication-title: Melanoma Res doi: 10.1097/00008390-200302000-00016 – volume: 29 start-page: 2208 year: 2018 ident: 10.1016/j.ejca.2022.04.018_bib127 article-title: Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer publication-title: Ann Oncol doi: 10.1093/annonc/mdy408 – volume: 153 start-page: 1278 year: 2017 ident: 10.1016/j.ejca.2022.04.018_bib29 article-title: Correlation of handheld reflectance confocal microscopy with radial video mosaicing for margin mapping of lentigo maligna and lentigo maligna melanoma publication-title: JAMA dermatology doi: 10.1001/jamadermatol.2017.3114 – volume: 127 start-page: 392 year: 1992 ident: 10.1016/j.ejca.2022.04.018_bib33 article-title: Technical details of intraoperative lymphatic mapping for early stage melanoma publication-title: Arch Surg doi: 10.1001/archsurg.1992.01420040034005 – volume: 18 start-page: 1040 year: 2017 ident: 10.1016/j.ejca.2022.04.018_bib74 article-title: Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(17)30414-X – volume: 28 start-page: 316 year: 2010 ident: 10.1016/j.ejca.2022.04.018_bib5 article-title: Incisional biopsy and melanoma prognosis: Facts and controversies publication-title: Clin Dermatol doi: 10.1016/j.clindermatol.2009.06.013 – volume: 19 start-page: 672 year: 2018 ident: 10.1016/j.ejca.2022.04.018_bib64 article-title: Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(18)30139-6 – volume: 106 start-page: 375 year: 2006 ident: 10.1016/j.ejca.2022.04.018_bib173 article-title: Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma publication-title: Cancer doi: 10.1002/cncr.21611 – volume: 214 start-page: 491 year: 1991 ident: 10.1016/j.ejca.2022.04.018_bib46 article-title: Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic publication-title: Ann Surg doi: 10.1097/00000658-199110000-00013 – volume: 383 start-page: 816 year: 2014 ident: 10.1016/j.ejca.2022.04.018_bib1 article-title: Cutaneous melanoma publication-title: Lancet doi: 10.1016/S0140-6736(13)60802-8 – volume: 42 start-page: 73 year: 2016 ident: 10.1016/j.ejca.2022.04.018_bib13 article-title: Surgical excision margins in primary cutaneous melanoma: a meta-analysis and Bayesian probability evaluation publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2015.10.013 – volume: 39 start-page: 9506 year: 2021 ident: 10.1016/j.ejca.2022.04.018_bib132 article-title: CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma publication-title: J Clin Oncol doi: 10.1200/JCO.2021.39.15_suppl.9506 – volume: 110 start-page: 11 year: 2019 ident: 10.1016/j.ejca.2022.04.018_bib69 article-title: Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases publication-title: Eur J Cancer doi: 10.1016/j.ejca.2018.12.023 – volume: 67 start-page: 472 year: 2017 ident: 10.1016/j.ejca.2022.04.018_bib34 article-title: Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual publication-title: CA: a cancer journal for clinicians – volume: 51 start-page: 2404 year: 2015 ident: 10.1016/j.ejca.2022.04.018_bib199 article-title: Uveal melanoma UK national guidelines publication-title: Eur J Cancer doi: 10.1016/j.ejca.2015.07.013 – volume: 22 start-page: 53 year: 2004 ident: 10.1016/j.ejca.2022.04.018_bib85 article-title: Adjuvant interferon in high-risk melanoma: the AIM HIGH Study–United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma publication-title: J Clin Oncol doi: 10.1200/JCO.2004.03.185 – volume: 24 start-page: 4738 year: 2006 ident: 10.1016/j.ejca.2022.04.018_bib165 article-title: Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group publication-title: J Clin Oncol doi: 10.1200/JCO.2006.06.0483 – volume: 373 start-page: 1270 year: 2015 ident: 10.1016/j.ejca.2022.04.018_bib139 article-title: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1504030 – volume: 39 start-page: 9503 year: 2021 ident: 10.1016/j.ejca.2022.04.018_bib160 article-title: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: primary phase III results from RELATIVITY-047 (CA224-047) publication-title: J Clin Oncol doi: 10.1200/JCO.2021.39.15_suppl.9503 – volume: 190 start-page: 913 year: 2005 ident: 10.1016/j.ejca.2022.04.018_bib4 article-title: Is incisional biopsy of melanoma harmful? publication-title: Am J Surg doi: 10.1016/j.amjsurg.2005.08.020 – start-page: Cd010308 year: 2014 ident: 10.1016/j.ejca.2022.04.018_bib19 article-title: Interventions for melanoma in situ, including lentigo maligna publication-title: Cochrane Database Syst Rev – volume: 39 start-page: 9504 year: 2021 ident: 10.1016/j.ejca.2022.04.018_bib190 article-title: Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: updated findings of LEAP-004 publication-title: J Clin Oncol doi: 10.1200/JCO.2021.39.15_suppl.9504 – volume: 32 start-page: S867 issue: suppl_5 year: 2021 ident: 10.1016/j.ejca.2022.04.018_bib161 article-title: 1036O - relatlimab (RELA) + nivolumab (NIVO) vs. NIVO in previously untreated metastatic or unresectable melanoma: additional efficacy in RELATIVITY-047 publication-title: Ann Oncol doi: 10.1016/j.annonc.2021.08.1421 – volume: 144 start-page: 943 year: 2008 ident: 10.1016/j.ejca.2022.04.018_bib26 article-title: Imiquimod treatment of lentigo maligna: an open-label study of 34 primary lesions in 32 patients publication-title: Arch Dermatol doi: 10.1001/archderm.144.7.943 – volume: 17 start-page: 325 year: 2007 ident: 10.1016/j.ejca.2022.04.018_bib2 article-title: Management of adult patients with cutaneous melanoma without distant metastasis. 2005 update of the French Standards, Options and Recommendations guidelines. Summary report publication-title: Eur J Dermatol : EJD. – volume: 6 start-page: 285 year: 1989 ident: 10.1016/j.ejca.2022.04.018_bib167 article-title: Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: a randomized phase II study publication-title: Med Oncol Tumor Pharmacother doi: 10.1007/BF02985163 – volume: 39 start-page: 356154 year: 2021 ident: 10.1016/j.ejca.2022.04.018_bib157 article-title: DREAMseq (doublet, randomized evaluation in advanced melanoma sequencing): a phase III trial—ECOG-ACRIN EA6134 publication-title: J Clin Oncol doi: 10.1200/JCO.2021.39.36_suppl.356154 – volume: 370 start-page: 599 year: 2014 ident: 10.1016/j.ejca.2022.04.018_bib41 article-title: Final trial report of sentinel-node biopsy versus nodal observation in melanoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1310460 – volume: 23 start-page: 4178 year: 2016 ident: 10.1016/j.ejca.2022.04.018_bib39 article-title: Sentinel lymph node biopsy in thin cutaneous melanoma: a systematic review and meta-analysis publication-title: Ann Surg Oncol doi: 10.1245/s10434-016-5137-z – volume: 17 start-page: 184 year: 2016 ident: 10.1016/j.ejca.2022.04.018_bib12 article-title: Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)00482-9 – volume: 104 start-page: 111 year: 2011 ident: 10.1016/j.ejca.2022.04.018_bib54 article-title: Does metastasectomy improve survival in patients with Stage IV melanoma? A cancer registry analysis of outcomes publication-title: J Surg Oncol doi: 10.1002/jso.21903 – volume: 377 start-page: 1813 year: 2017 ident: 10.1016/j.ejca.2022.04.018_bib77 article-title: Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1708539 – volume: 39 start-page: 9507 year: 2021 ident: 10.1016/j.ejca.2022.04.018_bib146 article-title: Five-year overall survival (OS) in COLUMBUS: a randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma publication-title: J Clin Oncol doi: 10.1200/JCO.2021.39.15_suppl.9507 – volume: 132 start-page: S3 issue: 10 year: 2005 ident: 10.1016/j.ejca.2022.04.018_bib9 publication-title: Annales de dermatologie et de venereologie doi: 10.1016/S0151-9638(05)79450-3 – volume: 15 start-page: 859 year: 1988 ident: 10.1016/j.ejca.2022.04.018_bib60 article-title: Palliative radiotherapy for metastatic malignant melanoma: brain metastases, bone metastases, and spinal cord compression publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/0360-3016(88)90118-6 – volume: 9 start-page: 491 year: 1999 ident: 10.1016/j.ejca.2022.04.018_bib48 article-title: Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study publication-title: Melanoma Res doi: 10.1097/00008390-199910000-00009 – volume: 39 start-page: 9516 year: 2021 ident: 10.1016/j.ejca.2022.04.018_bib135 article-title: Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: three-year results of CheckMate 511 publication-title: J Clin Oncol doi: 10.1200/JCO.2021.39.15_suppl.9516 – volume: 12 year: 2020 ident: 10.1016/j.ejca.2022.04.018_bib191 article-title: Distinct mutation patterns reveal melanoma subtypes and influence immunotherapy response in advanced melanoma patients publication-title: Cancers doi: 10.3390/cancers12092359 – volume: 375 start-page: 1845 year: 2016 ident: 10.1016/j.ejca.2022.04.018_bib78 article-title: Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy publication-title: N Engl J Med doi: 10.1056/NEJMoa1611299 – volume: 39 start-page: 634 year: 2010 ident: 10.1016/j.ejca.2022.04.018_bib53 article-title: Surgical metastasectomy in AJCC stage IV M1c melanoma patients with gastrointestinal and liver metastases publication-title: Ann Acad Med Singapore doi: 10.47102/annals-acadmedsg.V39N8p634 – volume: 18 start-page: 1049 year: 2017 ident: 10.1016/j.ejca.2022.04.018_bib73 article-title: Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(17)30441-2 – volume: 62 start-page: 1061 year: 1988 ident: 10.1016/j.ejca.2022.04.018_bib174 article-title: Combination of cisplatin, vindesine, and dacarbazine in advanced malignant melanoma. A phase II study of the EORTC malignant melanoma cooperative group publication-title: Cancer doi: 10.1002/1097-0142(19880915)62:6<1061::AID-CNCR2820620607>3.0.CO;2-X – volume: 22 start-page: 836 year: 2021 ident: 10.1016/j.ejca.2022.04.018_bib187 article-title: Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(21)00097-8 – ident: 10.1016/j.ejca.2022.04.018_bib65 doi: 10.1200/JCO.2017.35.15_suppl.9507 – volume: 32 start-page: S867 issue: suppl_5 year: 2021 ident: 10.1016/j.ejca.2022.04.018_bib177 article-title: 1039MO - CheckMate 204: 3-year outcomes of treatment with combination nivolumab (NIVO) plus ipilimumab (IPI) for patients (pts) with active melanoma brain metastases (MBM) publication-title: Ann Oncol – volume: 16 start-page: 1049 year: 2015 ident: 10.1016/j.ejca.2022.04.018_bib58 article-title: Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)00187-4 – volume: 39 start-page: 9508 year: 2021 ident: 10.1016/j.ejca.2022.04.018_bib178 article-title: Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): randomized phase 2 study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets) publication-title: J Clin Oncol doi: 10.1200/JCO.2021.39.15_suppl.9508 – volume: 185 start-page: 675 year: 2021 ident: 10.1016/j.ejca.2022.04.018_bib25 article-title: Real-world experience of off-label use of imiquimod 5% as an adjuvant therapy after surgery or as a monotherapy for lentigo maligna publication-title: Br J Dermatol doi: 10.1111/bjd.20407 – volume: 17 start-page: 1248 year: 2016 ident: 10.1016/j.ejca.2022.04.018_bib140 article-title: Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)30122-X – volume: 381 start-page: 626 year: 2019 ident: 10.1016/j.ejca.2022.04.018_bib141 article-title: Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1904059 – volume: 392 start-page: 971 year: 2018 ident: 10.1016/j.ejca.2022.04.018_bib112 publication-title: Melanoma. The Lancet. doi: 10.1016/S0140-6736(18)31559-9 – volume: 17 start-page: 757 year: 2016 ident: 10.1016/j.ejca.2022.04.018_bib42 article-title: Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)00141-8 – volume: 381 start-page: 1535 year: 2019 ident: 10.1016/j.ejca.2022.04.018_bib131 article-title: Five-year survival with combined nivolumab and ipilimumab in advanced melanoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1910836 – volume: 31 start-page: 413 year: 2021 ident: 10.1016/j.ejca.2022.04.018_bib71 article-title: Combination of radiotherapy and targeted therapy for melanoma brain metastases: a systematic review publication-title: Melanoma Res doi: 10.1097/CMR.0000000000000761 – volume: 14 start-page: 7 year: 1996 ident: 10.1016/j.ejca.2022.04.018_bib92 article-title: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684 publication-title: J Clin Oncol doi: 10.1200/JCO.1996.14.1.7 – volume: 131 start-page: 68 year: 2020 ident: 10.1016/j.ejca.2022.04.018_bib130 article-title: A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation publication-title: Eur J Cancer doi: 10.1016/j.ejca.2020.02.016 – volume: 130 start-page: 126 year: 2020 ident: 10.1016/j.ejca.2022.04.018_bib155 article-title: Survival of patients with advanced metastatic melanoma: the impact of MAP kinase pathway inhibition and immune checkpoint inhibition - update 2019 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2020.02.021 – volume: 18 start-page: 2444 year: 2000 ident: 10.1016/j.ejca.2022.04.018_bib88 article-title: High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190 publication-title: J Clin Oncol doi: 10.1200/JCO.2000.18.12.2444 – volume: 9 start-page: 611 year: 1999 ident: 10.1016/j.ejca.2022.04.018_bib63 article-title: Radiotherapy as palliative treatment for metastatic melanoma publication-title: Melanoma Res doi: 10.1097/00008390-199912000-00012 – volume: 34 start-page: 147 year: 2008 ident: 10.1016/j.ejca.2022.04.018_bib28 article-title: Treatment of lentigo maligna with imiquimod before staged excision publication-title: Dermatol Surg doi: 10.1097/00042728-200802000-00002 – volume: 138 start-page: 11 year: 2020 ident: 10.1016/j.ejca.2022.04.018_bib196 article-title: Head and neck mucosal melanoma: the United Kingdom national guidelines publication-title: European Journal of Cancer doi: 10.1016/j.ejca.2020.07.017 – volume: 15 start-page: 954 year: 2014 ident: 10.1016/j.ejca.2022.04.018_bib152 article-title: Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)70301-8 – year: 2018 ident: 10.1016/j.ejca.2022.04.018_bib16 – volume: 13 start-page: 2776 year: 1995 ident: 10.1016/j.ejca.2022.04.018_bib93 article-title: Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma publication-title: J Clin Oncol doi: 10.1200/JCO.1995.13.11.2776 – volume: 31 start-page: S672 issue: suppl_4 year: 2020 ident: 10.1016/j.ejca.2022.04.018_bib204 article-title: 1080MO - the value of local therapy in treatment of solitary melanoma progression upon immune checkpoint inhibition publication-title: Ann Oncol – volume: 13 start-page: 1087 year: 2012 ident: 10.1016/j.ejca.2022.04.018_bib119 article-title: Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(12)70431-X – volume: 385 start-page: 1196 year: 2021 ident: 10.1016/j.ejca.2022.04.018_bib201 article-title: Overall survival benefit with tebentafusp in metastatic uveal melanoma publication-title: N Engl J Med doi: 10.1056/NEJMoa2103485 – volume: 31 start-page: 1075 year: 2020 ident: 10.1016/j.ejca.2022.04.018_bib203 article-title: Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy publication-title: Ann Oncol doi: 10.1016/j.annonc.2020.04.471 – volume: 16 start-page: 1389 year: 2015 ident: 10.1016/j.ejca.2022.04.018_bib142 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)00087-X – volume: 371 start-page: 1867 year: 2014 ident: 10.1016/j.ejca.2022.04.018_bib151 article-title: Combined vemurafenib and cobimetinib in BRAF-mutated melanoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1408868 – volume: 29 start-page: 2904 year: 2011 ident: 10.1016/j.ejca.2022.04.018_bib147 article-title: Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification publication-title: J Clin Oncol doi: 10.1200/JCO.2010.33.9275 – volume: 23 start-page: 1493 year: 1999 ident: 10.1016/j.ejca.2022.04.018_bib31 article-title: Patterns of local horizontal spread of melanomas: consequences for surgery and histopathologic investigation publication-title: Am J Surg Pathol doi: 10.1097/00000478-199912000-00006 – volume: 32 start-page: S867 issue: suppl_5 year: 2021 ident: 10.1016/j.ejca.2022.04.018_bib185 article-title: 1038MO - intracranial activity of encorafenib and binimetinib followed by radiotherapy in patients with BRAF mutated melanoma and brain metastasis: preliminary results of the GEM1802/EBRAIN-MEL phase II clinical trial publication-title: Ann Oncol |
| SSID | ssj0007840 |
| Score | 2.696505 |
| SecondaryResourceType | review_article |
| Snippet | A unique collaboration of multidisciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the... |
| SourceID | hal proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 256 |
| SubjectTerms | Adjuvant treatment Antibodies Antineoplastic Combined Chemotherapy Protocols Cancer Consensus CTLA-4 protein Cutaneous melanoma Dermatology Excisional margins Human health and pathology Humans Immunotherapy Inhibitor drugs Interdisciplinary aspects Interferon-α Life Sciences Literature reviews Lymph nodes MEK inhibitors Melanoma Melanoma - pathology Melanoma, Cutaneous Malignant Metastasectomy Metastases Mutation Neoplasm Staging Oncology Oximes Patients PD-1 protein Pharmaceutical sciences Pharmacology Proto-Oncogene Proteins B-raf - genetics Risk analysis Risk factors Safety margins Sentinel lymph node dissection Skin Neoplasms - genetics Surgery Systematic Reviews as Topic Systemic treatment Targeted cancer therapy Therapy Tumor thickness Tumors |
| Title | European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022 |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0959804922002283 https://dx.doi.org/10.1016/j.ejca.2022.04.018 https://www.ncbi.nlm.nih.gov/pubmed/35623961 https://www.proquest.com/docview/2691828210 https://www.proquest.com/docview/2671276012 https://hal.science/hal-03775755 |
| Volume | 170 |
| WOSCitedRecordID | wos000833527200004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1879-0852 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0007840 issn: 0959-8049 databaseCode: AIEXJ dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfaDU17mfimY0wG8VZlip04Tnir0GB8TTx0Ut8ix3EHVZtWaVKVR_5zznHs7oMOeOAlqpw4SXs_3_3uendG6HUeCSWJL72MBLkXBjHzMknGHlCPPFCcRUEmm80m-Pl5PBolXzudn7YWZjXlRRGv18niv4oaxkDYunT2H8TtbgoD8BmEDkcQOxz_SvAuvi51onSxrJeeNlV50xmivFaFe1nrJleaZ-pkw5maimI-EydAK8uqT5vIu8tD9_oXCx0d6FPflPj-Np7fclupsVQ2TaDADl2JNrwXZWZyD6eidnR-MBNls_FAf6jA_RcbfV2aFgifVFX92CjLetnUoDd6bd3m_LeRC7rJcgXDY7RtzBMPON91dWw2ErEK1bQdv6XoTcxhcqImUnePorRpWGtU-RUhL2aNlAPN8pKIbIyeS0W0p7pol3KWgGLcHXw4HX105pyDC9xWW5nEwJuP3Ed79ibbyE33m86y3ebCNFRmeB8dtD4IHhjsPEAdVTxEe1_aLItHKLMixTcghG9BCDsIYYAQdhDCGkKYvsEOQNjDBkBYf6nH6OLd6fDtmdfuxeFJxpPKCxWPFLB5JXNY0HmUxAJMg_TFmIcRUMRMRCwnLB4rmREYJLHiCZchESokXPnBE7RTzAv1DGHGxiGnGRgCkodUZDHNdBUdCcA7JoIlPUTsj5jKtlG93i9lmtqMxEmqZZDq1039MAUZ9FDfzVmYNi13Xh1Y2aS2ABlMZgrgunMWc7Naempo5x_nvQLxu9fS_dzPBp9TPeYHnIO_xFakh44sOtJ2uS5TGiXg_seU-D300p0G_a__1BOFmtf6Gk6oTmyjPfTUoMo9ysLycOuZ52h_szKP0E5V1uoFuidX1fdleYy6fBQftwviFzOw0CQ |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=European+consensus-based+interdisciplinary+guideline+for+melanoma.+Part+2%3A+Treatment+-+Update+2022&rft.jtitle=European+journal+of+cancer+%281990%29&rft.au=Garbe%2C+Claus&rft.au=Amaral%2C+Teresa&rft.au=Peris%2C+Ketty&rft.au=Hauschild%2C+Axel&rft.date=2022-07-01&rft.eissn=1879-0852&rft.volume=170&rft.spage=256&rft_id=info:doi/10.1016%2Fj.ejca.2022.04.018&rft_id=info%3Apmid%2F35623961&rft.externalDocID=35623961 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0959-8049&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0959-8049&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0959-8049&client=summon |